EP4074319A1 - Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye - Google Patents
Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye Download PDFInfo
- Publication number
- EP4074319A1 EP4074319A1 EP21382320.6A EP21382320A EP4074319A1 EP 4074319 A1 EP4074319 A1 EP 4074319A1 EP 21382320 A EP21382320 A EP 21382320A EP 4074319 A1 EP4074319 A1 EP 4074319A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- eye
- cerium oxide
- formula
- crystal
- colloidal suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 184
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 73
- 201000010099 disease Diseases 0.000 title claims abstract description 54
- 230000000699 topical effect Effects 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims description 35
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 title description 87
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 title description 35
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 claims abstract description 115
- 229910000420 cerium oxide Inorganic materials 0.000 claims abstract description 114
- 239000013078 crystal Substances 0.000 claims abstract description 96
- 239000000725 suspension Substances 0.000 claims abstract description 82
- 238000011282 treatment Methods 0.000 claims abstract description 54
- 208000035475 disorder Diseases 0.000 claims abstract description 19
- 239000003889 eye drop Substances 0.000 claims abstract description 16
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 31
- 210000001525 retina Anatomy 0.000 claims description 30
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 29
- 208000002780 macular degeneration Diseases 0.000 claims description 24
- 210000003161 choroid Anatomy 0.000 claims description 19
- 210000003786 sclera Anatomy 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 16
- 238000000576 coating method Methods 0.000 claims description 16
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 14
- 208000035719 Maculopathy Diseases 0.000 claims description 14
- 230000007170 pathology Effects 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 239000000969 carrier Substances 0.000 claims description 12
- 230000002207 retinal effect Effects 0.000 claims description 12
- 239000001509 sodium citrate Substances 0.000 claims description 12
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 12
- 208000010412 Glaucoma Diseases 0.000 claims description 10
- 238000002441 X-ray diffraction Methods 0.000 claims description 8
- -1 alkaline-earth metal salt Chemical class 0.000 claims description 8
- 210000001328 optic nerve Anatomy 0.000 claims description 8
- 238000004627 transmission electron microscopy Methods 0.000 claims description 7
- 208000001351 Epiretinal Membrane Diseases 0.000 claims description 6
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 6
- 208000033379 Chorioretinopathy Diseases 0.000 claims description 4
- 208000003435 Optic Neuritis Diseases 0.000 claims description 4
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038910 Retinitis Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000027073 Stargardt disease Diseases 0.000 claims description 4
- 208000014769 Usher Syndromes Diseases 0.000 claims description 4
- 208000034699 Vitreous floaters Diseases 0.000 claims description 4
- 208000029517 toxic amblyopia Diseases 0.000 claims description 4
- 208000001344 Macular Edema Diseases 0.000 claims description 3
- 206010025415 Macular oedema Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 201000010230 macular retinal edema Diseases 0.000 claims description 3
- 208000005598 Angioid Streaks Diseases 0.000 claims description 2
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 claims description 2
- 208000008319 Bietti crystalline dystrophy Diseases 0.000 claims description 2
- 208000016615 Central areolar choroidal dystrophy Diseases 0.000 claims description 2
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims description 2
- 208000033825 Chorioretinal atrophy Diseases 0.000 claims description 2
- 208000033810 Choroidal dystrophy Diseases 0.000 claims description 2
- 208000021089 Coats disease Diseases 0.000 claims description 2
- 201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 claims description 2
- 208000037312 Familial drusen Diseases 0.000 claims description 2
- 208000037060 Hyalosis asteroid Diseases 0.000 claims description 2
- 206010053678 Iridocorneal endothelial syndrome Diseases 0.000 claims description 2
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims description 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims description 2
- 206010059239 Leukaemic retinopathy Diseases 0.000 claims description 2
- 208000031471 Macular fibrosis Diseases 0.000 claims description 2
- 208000009857 Microaneurysm Diseases 0.000 claims description 2
- 206010030043 Ocular hypertension Diseases 0.000 claims description 2
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims description 2
- 208000009702 Optic Disk Drusen Diseases 0.000 claims description 2
- 208000036584 Optic disc drusen Diseases 0.000 claims description 2
- 206010061323 Optic neuropathy Diseases 0.000 claims description 2
- 201000010183 Papilledema Diseases 0.000 claims description 2
- 206010033712 Papilloedema Diseases 0.000 claims description 2
- 206010064714 Radiation retinopathy Diseases 0.000 claims description 2
- 208000021016 Retinal Arterial Macroaneurysm Diseases 0.000 claims description 2
- 208000002367 Retinal Perforations Diseases 0.000 claims description 2
- 206010064145 Retinal aneurysm Diseases 0.000 claims description 2
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 2
- 208000032458 Retinopathy solar Diseases 0.000 claims description 2
- 208000027077 Stickler syndrome Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 208000036866 Vitreoretinopathy Diseases 0.000 claims description 2
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims description 2
- 208000022482 Wagner disease Diseases 0.000 claims description 2
- 208000029977 White Dot Syndromes Diseases 0.000 claims description 2
- 208000023564 acute macular neuroretinopathy Diseases 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 201000006321 fundus dystrophy Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims description 2
- 201000001948 hypertensive retinopathy Diseases 0.000 claims description 2
- 230000000366 juvenile effect Effects 0.000 claims description 2
- 208000029233 macular holes Diseases 0.000 claims description 2
- 208000001491 myopia Diseases 0.000 claims description 2
- 230000004379 myopia Effects 0.000 claims description 2
- 201000002165 neuroretinitis Diseases 0.000 claims description 2
- 201000005799 nutritional optic neuropathy Diseases 0.000 claims description 2
- 208000001749 optic atrophy Diseases 0.000 claims description 2
- 210000003488 posterior eye segment Anatomy 0.000 claims description 2
- 201000009015 preretinal fibrosis Diseases 0.000 claims description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 2
- 208000032253 retinal ischemia Diseases 0.000 claims description 2
- 201000001184 retinal microaneurysm Diseases 0.000 claims description 2
- 230000004286 retinal pathology Effects 0.000 claims description 2
- 201000000824 solar retinopathy Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 208000009056 telangiectasis Diseases 0.000 claims description 2
- 208000000318 vitreous detachment Diseases 0.000 claims description 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 210000001508 eye Anatomy 0.000 description 97
- 210000004027 cell Anatomy 0.000 description 33
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 30
- 229910052684 Cerium Inorganic materials 0.000 description 28
- 238000002347 injection Methods 0.000 description 27
- 239000007924 injection Substances 0.000 description 27
- 238000011200 topical administration Methods 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000009826 distribution Methods 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 230000002265 prevention Effects 0.000 description 15
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 210000004087 cornea Anatomy 0.000 description 11
- 239000003642 reactive oxygen metabolite Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002296 dynamic light scattering Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 8
- 229960001790 sodium citrate Drugs 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000084 colloidal system Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 239000007900 aqueous suspension Substances 0.000 description 6
- 239000006196 drop Substances 0.000 description 6
- 229940012356 eye drops Drugs 0.000 description 6
- 238000007306 functionalization reaction Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 6
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 5
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- HSJPMRKMPBAUAU-UHFFFAOYSA-N cerium(3+);trinitrate Chemical compound [Ce+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O HSJPMRKMPBAUAU-UHFFFAOYSA-N 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 208000011325 dry age related macular degeneration Diseases 0.000 description 5
- 210000004088 microvessel Anatomy 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 201000004569 Blindness Diseases 0.000 description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000006174 pH buffer Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 210000004127 vitreous body Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 3
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000011814 C57BL/6N mouse Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- 206010018341 Gliosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003091 Methocel™ Polymers 0.000 description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 3
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 230000007387 gliosis Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 2
- KZXUORFYMZRABO-UHFFFAOYSA-N 3-aminobutane-1,2,2-triol Chemical compound CC(N)C(O)(O)CO KZXUORFYMZRABO-UHFFFAOYSA-N 0.000 description 2
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- 210000004155 blood-retinal barrier Anatomy 0.000 description 2
- 230000004378 blood-retinal barrier Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004240 ciliary body Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000011506 response to oxidative stress Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003274 Arthritis viral Diseases 0.000 description 1
- 241000437273 Auricularia cornea Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000008069 Geographic Atrophy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 210000005156 Müller Glia Anatomy 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JGVKQHLTCLZHFR-UHFFFAOYSA-H [Ra+2].[Ra+2].[Ra+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O Chemical compound [Ra+2].[Ra+2].[Ra+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JGVKQHLTCLZHFR-UHFFFAOYSA-H 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940006612 barium citrate Drugs 0.000 description 1
- PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- XSIFPSYPOVKYCO-UHFFFAOYSA-N benzoic acid butyl ester Natural products CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- XQTIWNLDFPPCIU-UHFFFAOYSA-N cerium(3+) Chemical class [Ce+3] XQTIWNLDFPPCIU-UHFFFAOYSA-N 0.000 description 1
- DLNAGPYXDXKSDK-UHFFFAOYSA-K cerium(3+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ce+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O DLNAGPYXDXKSDK-UHFFFAOYSA-K 0.000 description 1
- ITZXULOAYIAYNU-UHFFFAOYSA-N cerium(4+) Chemical class [Ce+4] ITZXULOAYIAYNU-UHFFFAOYSA-N 0.000 description 1
- 229910000421 cerium(III) oxide Inorganic materials 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940071264 lithium citrate Drugs 0.000 description 1
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000120 microwave digestion Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- PWQWICVUFSCLKH-UHFFFAOYSA-H triberyllium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Be+2].[Be+2].[Be+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PWQWICVUFSCLKH-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- QGAPCDHPGCYAKM-UHFFFAOYSA-H tristrontium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QGAPCDHPGCYAKM-UHFFFAOYSA-H 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to the field of medical approaches for ocular diseases of posterior segment of the eye.
- the invention also relates to ophthalmic compositions.
- Eye is a very complex organ with different specialized cells and tissues. Local and systemic diseases may affect the different regions of the eye, but the anatomy of the eye and complex physiology of the retina and optic nerve makes challenging the development of efficacious drugs.
- the anterior segment of the eye refers to the cornea, conjunctiva, anterior sclera (part of sclera that transitions anteriorly to become cornea at the limbus) iris, ciliary body, aqueous humour and the lens.
- the posterior segment of the eye also named posterior eye segment
- posterior eye segment includes the anterior hyaloid membrane and the structures behind this membrane, posterior sclera (part of sclera that transitions posteriorly into optic nerve dural sheet), the vitreous body (including vitreous humour and membrane), retina, macula, choroid and optic nerve.
- Posterior segment represents the two-thirds of the eye.
- the leading causes of vision impairment and irreversible blindness are diseases related with the posterior segment of the eye.
- Topical formulations are the least invasive route for ocular drug administration.
- Topical local administration is the main modality treatment for anterior segment disease.
- ocular barriers for avoiding pathogens to access also hinder drug delivery even to the anterior segment.
- blinking and tear film turnover designed to wash away foreign material and maintain a smooth clear anterior surface, also limits residence time of a drug.
- access to posterior segment is hindered by a closely packed corneal epithelium and stroma with varying lipophilicity (see Awwad et al., "Principles of Pharmacology in the Eye", British Journal of Pharmacology-2017, vol no. 174 Issue 23, pp.:4205-4223 ).
- the direction of aqueous flow in the eye is against direction of drug delivery via a topical route.
- IVT injections avoid all barriers and results in the greatest bioavailability. However, IVT injections imply several severe side-effects, such as retinal detachment. In addition, this kind of intervention is totally senseless at early stages of many of the disease of posterior segment of eye.
- Main posterior segment ophthalmic disorders include pathological neovascularization and ectopic proliferation, atrophy and nerve cell death, inflammation and infection, and detachment.
- Diseases and conditions commonly associated with these symptoms include macular degeneration (i.e. age-related macular degeneration), diabetic retinopathy, retinopathy of prematurity, retinitis pigmentosa, macular edema, glaucoma, posterior uveitis, endophthalmitis, ocular insult and ocular manifestation of systemic disease such as viral infection, arthritis and rosacea.
- AMD aged-related macular degeneration
- AMD retinal cell death occurs due to an increase of oxidative stress and inflammatory response.
- AMD is a neurodegenerative and complex disorder with multifactorial etiology affecting retina and that results in the progressive and irreversible loss of central vision.
- AMD is one of the major causes of blindness, together with diabetic retinopathy.
- AMD is a disease currently unavoidable that represents a major cause of blindness in people over 50 and affects millions of people worldwide.
- it is a disease orphan of treatment. At early stages no specific treatment is administered, rather than vitamins and antioxidants, as previously indicated.
- AMD is classified in two types: wet AMD and dry AMD.
- the wet form of macular degeneration is related to abnormal growth of blood vessels in the retina that can leak blood and can cause damage to photoreceptor cells and retinal detachment.
- Approved drugs for advanced stages of wet AMD include certain antibodies such as bevacizumab and ranibizumab intravitreal injections, which are aimed to slow progression of disease.
- dry AMD characterized by a massive atrophy of retinal cells in the macula, no specific treatment has been found effective and finally approved.
- DR diabetic retinopathy
- cerium oxide nanoparticles cerium oxide nanoparticles (ceria nanoparticles or Ceria NPs) have been disclosed for intravitreal injections to treat glaucoma, age-related macular degeneration (dry and wet forms) and diabetic retinopathy, among other diseases.
- ceria nanoparticles to inhibit reactive oxygen species (ROS) and promote longevity of retinal neurons.
- ROS reactive oxygen species
- Data are performed in rats to which an intravitreal injection of ceria nanoparticles of unknown diameter size and three-dimensional form was administered. Ultrafine particles are mentioned from 1 to 10 nm, and topical application is also mentioned, although no data are provided.
- Ceria NPs cerium oxide nanoparticles
- aqueous media comprising a citrate salt
- nanoparticles were, thus, isolated single nanoparticles in suspension and monodispersed (i.e., >90% of uniformity in size distribution). These particular suspensions could enter the posterior segment from the anterior segment and no particle aggregation was observed, thus avoiding any secondary effect due to the formation of the precipitates.
- the amount of Ceria NPs that reached the posterior segment was about 30-50 % of the amount that was finally detected in the several eye parts after being topically administered. These detected amounts achieved effective concentrations for abrogating the evolution of the diseases.
- no toxicity was observed in tissues where Ceria NPs were retained, and they were neither detected in liver nor in brain.
- the concentration reached in the different parts with topical administration was about half of the reached with intravitreal injection. These were therapeutically effective amounts and, thus, for the first time Ceria NPs could be used as an actual substitute of intravitreal injections for the treatment of disorders, conditions or diseases of the ocular posterior segment.
- Yet another advantage of the proposed Ceria NPs and related with the toxicity is that, according to preliminary results, the particles do not accumulate in the eye in case of overdose and any excess is quickly removed/rinsed away. This makes possible repeated administration schedules for more than one day (i.e., 7 days or more), since after seven days of application of the Ceria NPs in form of a collyrium, only a 4-fold increase of concentration was observed with indications of saturation.
- the invention relates to a single-crystal single cerium oxide nanoparticle of formula (I): NP-(C) (I), wherein NP is a single-crystal single cerium oxide (CeO 2 ) nanoparticle with a crystal diameter from 3 to 5 nm, and (C) is a coating of citrate molecules adsorbed on the NP, for use in the treatment of a disorder or disease of the posterior segment of the eye, wherein the treatment comprises administration of a topical ophthalmic dose of single-crystal single cerium oxide nanoparticles of formula (I).
- This aspect of the invention can also be formulated as the use of a single-crystal single cerium oxide nanoparticles of formula (I) for the manufacture of a medicament for the prevention and/or treatment of a disorder or disease of the posterior segment of the eye, wherein the prevention or treatment comprises administration of a topical ophthalmic dose of these nanoparticles of formula (I).
- the present invention also relates to a method for the topical eye (ophthalmic) treatment and/or prevention of a disorder or disease of the posterior segment of the eye, comprising administering (meaning topically administering in the eye) a topical ophthalmic dose of nanoparticles of formula (I), together with topical pharmaceutically or veterinary acceptable excipients and/or carriers, in a subject in need thereof, including a human.
- administering meaning topically administering in the eye
- topical pharmaceutically or veterinary acceptable excipients and/or carriers in a subject in need thereof, including a human.
- nanoparticles of formula (I) are referred along this description as coated Ceria-NP, coated CeO2-NP, CeO2-NP-(C), or simply NP-(C). In any case, and if not indicated to the contrary, they relate to the nanoparticles of the single-crystal oxide comprising the citrate molecules associated to or adsorbed or coating (used as synonymous) said single-crystal.
- the nanoparticles are particularly in form of an aqueous colloidal suspension comprising the single-crystal single cerium oxide nanoparticles of formula (I) (NPs-(C)) of formula (I)), and a pharmaceutically acceptable citrate salt.
- aqueous colloidal suspensions comprising a pharmaceutically acceptable citrate salt and nanoparticles of formula NP-(C) (I), wherein NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, and (C) is citrate adsorbed on, thus coating, the NP; being these suspensions for use in the treatment of a disorder or disease of the posterior segment of the eye, wherein the treatment comprises administration of a topical ophthalmic dose of the aqueous colloidal suspension.
- colloidal suspensions for the intended use are obtainable by preparing CeO 2 nanoparticles using a cerium (III) citrate complex as a precursor and the pH basic precipitation in the presence of an excess of the pharmaceutically acceptable citrate salt, this excess defined as an amount higher than the one needed to fully cover the CeO 2 nanoparticle available surface.
- Inventors have determined that for 1 mg/ml of CeO 2 nanoparticles the amount in excess of the pharmaceutically acceptable salt of citrate in the colloidal suspension is from 2 to 10 mM in order to have a stable active principle that is further dispersed, for example, in a methylcellulose solution or other cellulose polymers (see examples below where citrate coated CeO 2 NPs of formula (I), were dispersed into a solution containing 5% of methylcellulose to get a CeO 2 final concentration of 2 mg/ml of CeO 2 ).
- an aqueous colloidal suspension comprising a pharmaceutically acceptable citrate salt and nanoparticles of formula NP-(C) (I), obtainable by:
- Cerium nitrate in absence of the citrate salt, such as sodium citrate (SC), Cerium nitrate will precipitate in form of cerium oxide at RT (room Temperature) and basic pH, forming aggregates.
- the stability of the cerium bond with the salt of citrate e.g., Ce-SC bond
- T high temperature
- the colloidal suspensions of Ceria NPs of formula (I) include these nanoparticles as single-crystals (i.e. no aggregation of particles but isolated) with a diameter allowing the entering to the ocular posterior segment without precipitation in the aqueous suspension, in part due to the presence of the citrate molecules adsorbed on the single-crystal, or in other words making a kind of coating around it.
- Citrate molecules are associated by ionic or van der Waals forces with the cerium oxide surface of the nanoparticles, which acquire a net negative charge.
- colloidal particles are negatively charged.
- the nanoparticles surface is free of any functionalization by molecules of hydrophobic or amphiphilic nature (i.e., polyethylene glycols, saccharides) and free of encapsulating carriers (i.e., liposomes, exosomes, etc.). Avoidance of functionalization is of interest, since the more complex the molecules, the more reactive generally to immune system of the host.
- molecules of hydrophobic or amphiphilic nature i.e., polyethylene glycols, saccharides
- encapsulating carriers i.e., liposomes, exosomes, etc.
- This second aspect of the invention can also be formulated as the use of aqueous colloidal suspensions comprising single-crystal single cerium oxide nanoparticles of formula (I) as defined above (i.e. NP-(C)), and a pharmaceutically acceptable citrate salt, for the manufacture of a medicament for the prevention and/or treatment of a disorder or disease of the posterior segment of the eye, wherein the prevention or treatment comprises administration of a topical ophthalmic dose of these aqueous colloidal suspensions.
- aqueous colloidal suspensions comprising single-crystal single cerium oxide nanoparticles of formula (I) as defined above (i.e. NP-(C)), and a pharmaceutically acceptable citrate salt
- the present invention also relates to a method for the topical eye (ophthalmic) treatment and/or prevention of a disorder or disease of the posterior segment of the eye, comprising administering (meaning topically administering in the eye) a topical ophthalmic dose of an aqueous colloidal suspension comprising single-crystal single cerium oxide nanoparticles of formula (I) (i.e. NP-(C)) as defined above, and a pharmaceutically acceptable citrate salt, together with topical pharmaceutically or veterinary acceptable excipients and/or carriers, in a subject in need thereof, including a human.
- a topical eye ophthalmic
- a third aspect of the invention is a pharmaceutical or veterinary composition comprising:
- NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, measured with transmission electron microscopy and X-Ray diffraction, and (C) is citrate molecules adsorbed on, thus coating, the NP; and (b) a pharmaceutically or veterinary acceptable citrate salt, together with pharmaceutically or veterinary acceptable excipients and/or carriers.
- compositions when formulated in particular as pharmaceutical or veterinary topical eye colloidal suspensions comprising the nanoparticles in colloidal suspension and the pharmaceutically or veterinary acceptable citrate salt, allow high penetration percentages of the active into the posterior segment, and a uniform distribution within all the structures therein, although topically applied (i.e., through cornea, sclera or conjunctiva).
- single-crystal single cerium oxide nanoparticle it is to be understood that said nanoparticle is not aggregated (by weak or strong physical interaction) with other nanoparticles. Thus, it is isolated as a mono-nanoparticle or monodispersed. They are also termed “single crystallites of cerium oxide”. For example, single 3-5 nm crystallites of cerium oxide. All these structures can be seen by TEM. With the TEM technology high electron density of the Cerium atoms coupled to oxygen can be visualized. With X-ray technology crystal domains (group of atoms in columns and rows in the same crystal structure) are detected.
- single-crystal or monocrystal means that there is only one crystal of cerium oxide configuring the nanoparticle, which has a particular crystal diameter.
- the X-ray diffraction detected crystal domain is highly similar with the diameter detected by TEM, which is the prove that nanoparticles are not aggregated, as DLS measurements corroborate ( FIG.7 ).
- nanoparticle refers generally to a particle with at least two dimensions at the nanoscale, particularly with all three dimensions at the nanoscale (1-100 nm).
- the nanoparticles are in the range about 3 nm to about 5 nm, including 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9 and 5. More particularly in the range from 3.0 to 3.5 nm.
- shape of the nanoparticles described herein there are included spheres and polyhedral. In a particular embodiment the nanoparticle is spherical.
- the term "size" refers to a characteristic physical dimension.
- the size of the nanoparticle corresponds to the diameter of the nanoparticle.
- the set of nanoparticles can have a distribution of sizes around the specified size.
- a size of a set of nanoparticles can refer to a mode of a distribution of sizes, such as a peak size of the distribution of sizes.
- the diameter is the equivalent diameter of the spherical body including the object.
- cerium oxide refers to cerium (III) oxide (Ce 3+ ) and cerium (IV) oxide (Ce 4+ ) species that are both present when constituting the nanoparticles. Although many of the cerium atoms in cerium oxide nanoparticles are usually in the (Ce 4+ ) oxidation state, small cerium oxide nanoparticles also contain cerium atoms in the (Ce 3+ ) oxidation state. Cerium oxide nanoparticles (abbreviated also as Ceria NPs, CeO 2 -NP or simply CNP) are used in a variety of applications mainly due to its high surface area and the ability of cerium oxide to cycle between (III and IV) oxidation states. In a particular embodiment, cerium oxide nanoparticles are in the (Ce 4+ ) oxidation state.
- the diameter of the nanoparticle When in this description the diameter of the nanoparticle is mentioned, it relates to the crystal size diameter (single crystal). As previously indicated, crystal size is usually measured from X-ray diffraction patterns while particle size is measured by TEM. In the case of single-crystal nanoparticles, XRD, TEM and DLS sizes coincide. Typical crystal size diameters of the nanoparticles used in the present invention range from 3 to 5 nm, when measured by TEM, more particularly the crystal size diameter of the nanoparticles is about 5 nm.
- the "hydrodynamic diameter” determined by dynamic light scattering (DLS) techniques based on the Stoke-Einstein equation is used herewith to refer to the single-crystal nanoparticle with adsorbed water and other molecules in the colloidal suspension. It can be measured by illuminating the particles with a laser and analyzing the intensity fluctuations in the scattered light. Dynamic light scattering measures Brownian motion and relates it to the size of the particles for which light intensity is proportional to the square of the volume of the particle. Therefore, the hydrodynamic size is always larger than the size observed by transmission electron microscopy, this later the one of the single-crystal nanoparticles. Typical hydrodynamic diameters of the single-crystal cerium oxide nanoparticles for use in present invention (highly monodispersed nanoparticles) gave a peak around 5 nm, which was much the same as TEM and XRD)
- a colloid In chemistry, a colloid is a mixture in which one substance of microscopically dispersed insoluble particles is suspended throughout another substance. Sometimes the dispersed substance alone is called the colloid; the term colloidal suspension refers unambiguously to the overall mixture. Unlike a solution, whose solute and solvent constitute only one phase, a colloid has a dispersed phase (the suspended particles) and a continuous phase (the medium of suspension) that arise by phase separation. To qualify as a colloid, the mixture must be one that does not settle or would take a very long time to settle appreciably.
- the dispersed phase are the single-crystals of single Ceria NPs (3-5 nm) with the associated citrate (C) molecules (citrate coating) on their surface, and the continuous phase where particles are suspended is a solvent, preferably a polar solvent (i.e. water, optionally buffered) comprising also the pharmaceutically acceptable citrate salts (in excess).
- a solvent preferably a polar solvent (i.e. water, optionally buffered) comprising also the pharmaceutically acceptable citrate salts (in excess).
- therapeutically effective amount refers to the amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disease which is addressed.
- the particular dose of compound administered according to this invention will of course be determined by the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated, and the similar considerations.
- pharmaceutically or veterinary acceptable refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical and veterinary judgment, suitable for use in contact with the tissues of a subject (e.g. human or any other animal) without significant toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- a subject e.g. human or any other animal
- Each carrier, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the pharmaceutical composition. It must also be suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications commensurate with a reasonable benefit/risk ratio.
- the inventors propose a new therapeutically approach for disorders, conditions or diseases of the posterior segment of the eye.
- NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm
- (C) is a coating of citrate molecules adsorbed on the NP, are proposed for use in the treatment of a disorder or disease of the posterior segment of the eye, wherein the treatment comprises administration of a topical ophthalmic dose of aqueous colloidal suspension.
- the single-crystal single cerium oxide nanoparticles have a crystal diameter from 3 to 3.5 nm measured by TEM. This means that the single-crystal single cerium oxide nanoparticles have a crystal diameter selected from 3.0, 3.1, 3.2, 3.3, 3.4, 3.5 nm, as the mean of crystal diameter of the distribution of sizes.
- the second aspect of the invention relates to aqueous colloidal suspensions comprising a pharmaceutically acceptable citrate salt and nanoparticles of formula NP-(C) (I), wherein NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, and (C) is citrate adsorbed on, thus coating, the NP; being these suspensions for use in the treatment of a disorder or disease of the posterior segment of the eye, wherein the treatment comprises administration of a topical ophthalmic dose of aqueous colloidal suspension.
- the single crystal single cerium oxide nanoparticles have a crystal diameter from 3 to 3.5 nm measured by TEM. This means that the single crystal cerium oxide nanoparticles have a crystal diameter selected from 3.0, 3.1, 3.2, 3.3, 3.4, 3.5 nm, as the mean of crystal diameter of the distribution of sizes.
- the pharmaceutically acceptable citrate salt in the colloidal suspension is selected from an alkaline and an alkaline-earth metal salt, or combinations thereof.
- it is selected from a pharmaceutically acceptable lithium citrate, sodium citrate, potassium citrate, beryllium citrate, magnesium citrate, calcium citrate, strontium citrate, barium citrate and radium citrate.
- sodium citrate is sodium citrate.
- Aqueous colloidal suspensions for use according to the second aspect comprise, in a particular embodiment, the pharmaceutically acceptable citrate salt at a final concentration from 1.0 to 20 mM. More in particular, from 2.0 to 10 mM.
- Doses of the topical ophthalmic route could be adjusted from 1.0 to 250 micrograms of the CeO 2 in the form of the nanoparticles of formula (I) per day (micrograms/eye/day). These doses include very low, but effective doses. This supposes the advantage of null side-effects while effectivity is maintained, precisely due to the "catalytic behavior" of ceria.
- final pharmaceutical composition can be afforded for an appropriate cost to consumer.
- Doses and concentrations of the nanoparticles of formula (I) in this description are indicated using the administered amount in micrograms/eye/day of cerium oxide (which is in the form of the citrated coated nanoparticles), or the concentration of this cerium oxide in the administered composition (in mg/ml or in the equivalent molarity according to cerium oxide molecular weight; 172.11 g/ml).
- concentration of this cerium oxide in the administered composition in mg/ml or in the equivalent molarity according to cerium oxide molecular weight; 172.11 g/ml.
- the aqueous colloidal suspension for use according to this aspect of the invention is, in a particular embodiment, an eye drop colloidal suspension.
- the colloidal suspension comprising the ceria NPs of formula (I) and the pharmaceutically acceptable citrate salt also includes excipients and carriers, such as buffer systems and preservatives.
- the pharmaceutical or veterinary topical eye drop colloidal suspension are to be understood as topical eye compositions applicable to the cornea, sclera or to the conjunctival fornix.
- particular ophthalmic doses of cerium oxide administered in this form of nanoparticles of formula (I) in the aqueous suspensions are from 1.0 to 250.0 micrograms of cerium oxide/day (i.e., micrograms/eye/day).
- the ophthalmic doses are from 1.0 to 100.0 micrograms/day.
- they are from 2.0 to 50.0 micrograms/day, even more in particular from 5.0 to 50.0 micrograms/day.
- these aqueous colloidal suspensions are in form of eye drops they are generally used in volumes of 30 to 50 microliters/drop, more in particular 50 microliters/drop.
- These doses can be applied once a day or more than once a day. They can also be maintained for one or several weeks.
- the ophthalmic dose of cerium oxide is administered from an aqueous colloidal suspension comprising from 1.0 to 5.0 mg/ml, more in particular from 2.0 to 4.0 mg/ml of cerium oxide as the single-crystal single cerium oxide nanoparticles of formula (I), stabilized in the excess of the pharmaceutical citrate salt.
- cerium oxide is at a concentration selected from 1.0, 2.0, 3.0, 4.0, 5.0 mg/ml.
- the aqueous suspension for the proposed use comprises 2 mg/ml of the cerium oxide in form of the single-crystal single cerium oxide nanoparticles of formula (I), wherein the crystal diameter of CeO 2 NPs is of 3.5 nm measured by TEM, and wherein the final ophthalmic dose of the cerium oxide in form of the single-crystal single cerium oxide nanoparticles of formula (I) is from 1.0 to 250 micrograms/eye/day.
- the aim of this invention is to focus on every ocular disease of the posterior segment, in which there is an inconvenient pro-inflammatory state and general oxidative stress, mainly caused by ROS, which damage the structures and worsens the disease, if already manifested, from an acute stage to a chronic stage.
- ROS general oxidative stress
- the eye disease is any disorder of any of the structures or tissues of the posterior segment, in that beside the primary disease cause (genetic, multifactorial, trauma, cancer, ...), inconvenient pro-inflammatory state and general oxidative stress environment is present. This is common to all diseases listed below.
- the single-crystal single nanoparticle and the aqueous colloidal suspension is for use in the prevention and/or treatment of a condition or disease of the posterior segment of the eye selected from the group consisting of retinal and/or choroid pathologies, vitreous humour pathologies, posterior sclera pathology, optic nerve pathologies, intraocular tumors, and combinations thereof.
- the disease of the posterior segment of the eye is a retinal pathology and/or choroid pathology selected from a retinal vasculopathy, a maculopathy, an hereditary eye fundus dystrophy, an idiopathic chorioretinopathy, a central serous retinopathy, generalized choroidal dystrophy, retinoblastoma, and combinations thereof.
- the single-crystal single nanoparticle or the aqueous colloidal suspension comprising the nanoparticles is for use in the prevention and/or treatment of a retinal vasculopathy selected from diabetic retinopathy, diabetic papillopathy, non-diabetic retinopathy, ocular ischemic syndrome, hypertensive retinopathy, thalassemia retinopathy, Coats' syndrome, Eales' syndrome, radiation retinopathy, solar retinopathy, purtscher retinopathy, polypoidal choroidal vasculopathy (PCV), retinal macroaneurysm, retinal microaneurysm, leukemic retinopathy, retinal ischemia, chronic retina disorders, and combinations thereof.
- a retinal vasculopathy selected from diabetic retinopathy, diabetic papillopathy, non-diabetic retinopathy, ocular ischemic syndrome, hypertensive retinopathy, thalassemia retinopathy, Coats
- the single-crystal single nanoparticle or the aqueous colloidal suspension is for use in the prevention and/or treatment of diabetic retinopathy, even more in particular early stages of the disease when intravitreal injections are not adequate due to their associated risks.
- the single-crystal single nanoparticle, or the aqueous colloidal suspension comprising it is for use in the prevention and/or treatment of a maculopathy selected from aged-related macular degeneration (AMD), retinal angiomatous proliferation, polipoidal choroidal vasculopathy, malattia leventinese, full thickness macular hole, macular epiretinal membrane, macular telangiectasias, cellophane maculopathy or macular pucker, myopia maculopathy, exudative maculopathy after venous thrombosis of the retina, acute macular neuroretinopathy, macular cystoids, macular edema, retinal angioid streaks, choroidal folds, hypotony maculopathy and combinations thereof; and wherein the hereditary eye fundus distrophy is selected from the group consisting of retinitis pigmentosa; atypical retinitis pigmentosa including but not limited to Usher's syndrome,
- the single-crystal single cerium oxide nanoparticle of formula (I), or the aqueous colloidal suspension, as above disclosed is for use in the prevention and/or treatment of AMD selected from wet AMD and dry AMD (geographic atrophy). In a more particular embodiment is for use in dry AMD. In another particular embodiment is for use in the prevention and/or treatment of retinitis pigmentosa.
- the single-crystal single cerium oxide nanoparticle of formula (I), or the aqueous colloidal suspension comprising it is for use in the prevention and/or treatment of a vitreous humour pathology selected from the group consisting of sub-macular and vitreous haemorrhages, asteroid hyalosis, vitreous detachment, eye floaters or myodesopsia, hereditary vitreoretinopathies, Stickler's syndrome or Wagner's Syndrome, and combinations thereof.
- a vitreous humour pathology selected from the group consisting of sub-macular and vitreous haemorrhages, asteroid hyalosis, vitreous detachment, eye floaters or myodesopsia, hereditary vitreoretinopathies, Stickler's syndrome or Wagner's Syndrome, and combinations thereof.
- the single-crystal single cerium oxide nanoparticle of formula (I), or the aqueous colloidal suspension comprising it is for use in the prevention and/or treatment of an optic nerve pathology selected from the group consisting of optic atrophy, optic neuritis, neuroretinitis, ischemic neuropathy, hereditary optic neuropathy, toxic amblyopia or nutritional optic neuropathy, ocular hypertension, primary glaucoma , secondary glaucoma, iridocorneal endothelial syndrome associated to glaucoma, head drusen or optic disc drusen, papilledema and combinations thereof.
- an optic nerve pathology selected from the group consisting of optic atrophy, optic neuritis, neuroretinitis, ischemic neuropathy, hereditary optic neuropathy, toxic amblyopia or nutritional optic neuropathy, ocular hypertension, primary glaucoma , secondary glaucoma, iridocorneal endothelial syndrome associated to glaucoma, head
- composition comprising:
- composition it is a pharmaceutical or veterinary topical eye colloidal suspension comprising:
- NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, measured with transmission electron microscopy and X-Ray diffraction, and (C) is citrate adsorbed on, thus coating, the NP; and (b) a pharmaceutically or veterinary acceptable citrate salt, together with topical ophthalmic pharmaceutically or veterinary acceptable excipients and/or carriers.
- the pharmaceutical or veterinary topical eye colloidal suspension comprises single-crystal single cerium oxide nanoparticle of formula (I) giving an amount in the suspension from 1.0 mg/ml to 5.0 mg/ml of the cerium oxide. More in particular, it comprises single-crystal single cerium oxide nanoparticle of formula (I) giving an amount from 2.0 mg/ml to 4.0 mg/ml of cerium oxide; even more in particular of 2.0 mg/ml).
- the pharmaceutically acceptable citrate salt in the pharmaceutical or veterinary composition is at a final concentration from 1.0 to 20 mM. More in particular, from 2.0 to 10 mM.
- topical eye aqueous colloidal suspension in also another particular embodiment, optionally in combination with any of the embodiments above or below of these topical eye aqueous colloidal suspensions, it has a viscosity from 3000-5500 mPa.
- compositions of the invention have a dynamic viscosity from 3000 to 5500mPa, at room temperature (i.e., 20 ⁇ 0.1 °C) and normal atmospheric pressure.
- dynamic viscosity or viscosity coefficient ⁇ is the tangential force per unit surface, known as shearing stress T and expressed in pascals, necessary to move, parallel to the sliding plane, a layer of liquid of 1 square meter at a rate (v) of 1 meter per second relative to a parallel layer at a distance (x) of 1 meter.
- the unit of dynamic viscosity is the pascal second (Pa.s).
- the topical eye aqueous colloidal suspension optionally in combination with any of the embodiments above or below of these topical eye aqueous colloidal suspensions, it comprises single-crystal single cerium oxide nanoparticles of formula (I) (i.e. citrate coated CeO 2 NPs) dispersed in a polar solvent, said solvent comprising water, a citrate salt (i.e. sodium citrate), the viscosity agent hydroxypropyl methylcellulose, the preservatives benzalkonium chloride and boric acid, and the tensoactive amino hydroxy methyl propanediol.
- formula (I) i.e. citrate coated CeO 2 NPs
- a polar solvent said solvent comprising water, a citrate salt (i.e. sodium citrate), the viscosity agent hydroxypropyl methylcellulose, the preservatives benzalkonium chloride and boric acid, and the tensoactive amino hydroxy methyl propanediol.
- aqueous (i.e., for eye drop) colloidal suspensions of the present invention may contain other ingredients, such as fragrances, colorants, and other components known in the state of the art for use in topical eye formulations.
- Topical eye compositions of the present invention can be prepared according to methods well known in the state of the art.
- the appropriate excipients and/or carriers, as well as any pH buffer, and their amounts, can readily be determined by those skilled in the art according to the type of formulation being prepared.
- Components in the topical eye (ophthalmic) composition of the invention include, in some particular embodiments, tensoactives, solvents (organic and inorganic solvents; i.e. water), viscosity agents, preservatives, agglutinants, emollients, and antioxidants, isotonifying and/or isoosmozing agents, and mucoadhesive polymers.
- viscosity agents are in particular polyvynil alcohol, compounds derived from cellulose such as methylcellulose and hydroxypropylmethylcellulose, carbomers, PEG and mixtures thereof.
- Other preservatives are in particular, benzoic acid, p-hydroxybenzoic esters of C1-C4-alkyl chains (i.e. methyl-, ethyl-, propyl-, and butyl-p-benzoate), chlorobuthanol, benzyl alcohol, and mixtures thereof.
- Isotonifying and/or isoosmozing agents are in particular sodium chloride, dextrose, trehalose, mannitol, amino acids and mixtures thereof.
- Excipients used as pH buffers are those allowing a pH from 4.5 to 9.0, more in particular from 4.5 to 8.5, even more in particular from 6.0 to 8.2, and preferably from 7.0 to 8.1, even more preferably from 7.5 to 8.0.
- pH buffers examples include citrate salts (citric acid/citrate buffer), which is this case is constituting the aqueous colloidal suspension, phosphate salts (phosporic acid/phosphate buffer), borate salts (boric acid/borate buffer), and mixtures thereof, all salts being those pharmaceuticaly accepatble.
- pH buffers may in additional comprise amino acids, in particular arginine, lysine, and an amine-derived compound selected from methylglucamine and trometamol, and mixtures thereof.
- the pharmaceutical or veterinary composition comprising: (a) a therapeutically effective amount of single-crystal single cerium oxide nanoparticles of formula (I); and (b) a pharmaceutically or veterinary acceptable citrate salt, together with pharmaceutically or veterinary acceptable excipients and/or carriers, are in a particular embodiment in a form selected from solutions, creams, lotions, unguents, emulsions, and suspensions.
- These particular compositions comprise, in even a more particular embodiment, topical pharmaceutically or veterinary acceptable excipients and/or carriers. More in particular, these topical compositions, in any of the forms, are also conceived for application onto skin and mucosae.
- TMAOH tetramethylamoniun hydroxide
- SC sodium citrate
- the nanoparticles were single-crystal single cerium oxide nanoparticles of formula (I) (NP-(C)), as revealed by TEM (see below in Results section), with CeO 2 NPs colloids of 3.0-3.5 nm diameter stable in water comprising the citrate salt, being part of the citrate associated or adsorbed (i.e. coating) on the single-crystal.
- Methocel ® 20% (Omnivision AG, Neuhausen, Switzerland) was used to prepare the CeO 2 NPs-based eye drops.
- 1 ml Methocel ® contains, according to the manufacturer specifications, 20 mg hydroxypropyl methylcellulose, 0.1 mg benzalkonium chloride, boric acid, amino hydroxy methyl propanediol and water. It has a viscosity of 3000-5500 mPa.s.
- the Methocel ® 20% was diluted four times in distilled H 2 O (thus, hydroxypropyl methylcellulose was at 5% of weight), and citrate coated CeO 2 NPs of formula (I) were dispersed into this solution at a final concentration of 2 mg/ml of CeO 2 under vigorous stirring.
- the prepared eye drop formulation was able for pipetting and thus, no errors in the administered dose could be induced by the solution viscosity.
- ARPE19 cells (commercially available) were maintained in Dulbecco's modified Eagle's medium/nutrient mixture F-12 (DMEM/F12), supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin-streptomycin, in a humidified incubator at 37°C and 5%CO 2 . For all experiments, cells between passages 6 and 12 were used.
- DMEM/F12 Dulbecco's modified Eagle's medium/nutrient mixture F-12
- FBS Fetal Bovine Serum
- penicillin-streptomycin penicillin-streptomycin
- ARPE19 cells (commercially available from ATCC) were seeded in 24-well plates (Sarstedt) at a density of 100.000 cells/ml in complete medium (DMEMF12 + 10% FBS + antibiotic) and incubated for 36h.
- Cerium oxide nanoparticles of formula (I) were added at final concentrations of cerium oxide of 10 nM, 50 nM, 100 nM and 500 nM (0.0017, 0.0086, 0.0172 and 0.0860 ⁇ g/ml) in fresh media and cells were incubated for 24 or 48h more.
- MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide
- ROS Reactive oxygen species
- Intracellular ROS levels were quantified using the H 2 DCFDA probe.
- ARPE19 cells were seeded in 24-well plates at a density of 100.000 cells/ml in complete medium and incubated for 36h.
- Cerium oxide nanoparticles of formula (I) were added at final concentrations of cerium oxide of 1 nM, 5 nM, 10 nM, 20 nM, 50 nM, 100 nM and 500 nM (from 0.00017 ⁇ g/ml to 0.086 ⁇ g/ml) in fresh media and incubated for 24h.
- Cells were washed with PBS 1X , H 2 DCFDA was added in fresh medium at a final concentration of 10 ⁇ M and incubated for 30min.
- mice Male 8-weeks old C57BL/6N mice purchased at Charles River (France) were used in CeO 2 NPs of formula (I) biodistribution experiments. Mice were maintained at CELLEX facilities under standard cyclic light conditions (12h light/12h darkness), free access to filtered water and ad libitum food. All experiments were performed according to the Association for Research in Vision and Ophthalmology statement for the use of animals in vision and ophthalmic research and approved by the Vall d'Hebron Research Institute Ethical Committee for Animal Research (VHIR-CEEA) and local governmental authorities.
- VHIR-CEEA Vall d'Hebron Research Institute Ethical Committee for Animal Research
- mice were anesthetized with inhaled 2% isofluorane (Aerrane ® , Baxter laboratories) in an induction chamber and their pupils were dilated with one drop of Tropicamide (Alcon Laboratories). Each animal was afterwards placed on a heating pad with an anaesthetic mask. Under a surgical microscope, a 36-gauge bevelled needle (Hamilton) was inserted in the sclera at approximately 1mm from the superior limbus and 1 ⁇ l of the correspondent solution (2 mg/ml) was administered (2 ⁇ g CeO 2 total). The eye fundus was visualized right after in a Micron III (Phoenix Research Lab) platform to corroborate the correct injection.
- isofluorane Analogenix Research Lab
- mice were slightly anesthetized with inhaled 2% isofluorane to guarantee a correct absorption and 5 ⁇ l (10 ⁇ g CeO 2 total) of the correspondent treatment (eye drop formulation of CeO 2 NPs of formula (I) giving 2 mg/ml of cerium oxide in the formulation) where placed on the cornea surface of each eye with a micropipette. Mice received the same treatment in both eyes to avoid cross-contamination.
- ICP-MS Inductively coupled plasma mass spectrometry
- mice were euthanized with inhaled CO 2 at designated time points post injection. Eyes were enucleated and fixed in 4% PFA (paraformaldehyde - dissolved in 1X PBS) for 30min before dissection under a stereomicroscope. Different ocular parts including anterior pole (cornea and iris), lens, retina, posterior pole (retinal pigment epithelium, choroid and sclera) and optic nerve were dissected and stored at -80°C until digestion. The brain and liver of each animal were also removed, immediately dry frozen and stored at 80°C. Organs were digested in concentrated HNO3 in a 1900 W microwave digestion oven (Milestone, ETHOS EASY). The resultant digestions were diluted with HNO3 1% (v/v) before being injected in the ICP-MS instrument (Agilent, 7500ce).
- mice were anesthetized with 1ml ketamine/0.3ml xylazine and transcardially perfused with 4%PFA. Eyes were enucleated and fixed with 4% PFA for 4h at RT and embedded in paraffin blocks. Eye sections of 3 ⁇ m were cut in a microtome and stored at 4°C. For histological evaluation, slides were deparaffinised in xylene and rehydrated in ethanol at decreasing concentrations. The sections were fixed in ice-cold methanol/acetic acid solution (95:5 v/v) for 1min. Haematoxylin and eosin staining was carried out with a standard protocol and slides were mounted with DPX mounting medium (VWR) and visualized in the microscope.
- VWR DPX mounting medium
- Slides were deparaffinised, rehydrated and fixed as described above. After the fixation, slides were washed three times with PBS 1X and antigen retrieval was performed by immersing them in sodium citrate buffer pH 6 and heating them in a pressure cooker for 4min. Samples were blocked with a solution containing 1% (v/v) BSA, 3% (v/v) NGS and 0.5% (v/v) Tween-20 in PBS for 1h at room temperature. Primary antibodies were incubated overnight at 4°C. The following day, samples were washed with PBS and secondary antibodies were incubated 1h at room temperature in darkness.
- ARPE-19 cells were seeded in a 12-well plate at a density of 100.000cells/ml. After 36h, cerium oxide nanoparticles were added at final concentrations of 50 and 500nM in fresh media and cells were incubated overnight. Cells were exposed to tBH for 4h to induce changes in gene expression. Then, they were washed with PBS 1X and Tri Reagent (Sigma) was added into each well before scrapping the cells. RNA was extracted using manufacturer's protocol.
- RNA pre-treated with DNase I (Life Technologies, Thermo) was used to synthetize first strand cDNA using the High-Capacity Reverse Transcription kit (Applied Biosystems, Thermo) with oligo(dT) Primers (Thermo).
- Quantitative real-time PCR was performed with LightCycler 480 SYBR Green I Master (Roche). Genes analysed were SOD2 and Nrf2. Gene expression was normalized to GAPDH. Animals were euthanized by CO 2 inhalation and eyes were immediately enucleated. Eyes were dissected under a stereomicroscope and neural retina, EPR, choroid and sclera were frozen in liquid nitrogen. RNA from the homogenized tissue was extracted using the Tri Reagent standard protocol. Synthesis of cDNA and qPCR were performed as explained above. Genes analysed were GFAP, SOD2 and Nrf2.Gene expression was normalized to B2M.
- Murine eyes of C57BL/6N were immediately enucleated and kept in ice-cold medium before dissection. After removing the cornea and the lens from the anterior of the eye, the central or peripheral choroid-scleral complex was separated from the retina and cut into approximately ⁇ 2 mmx1 mm pieces (rats) or 1 mm ⁇ 1 mm (mice). Choroid+sclera (here on referred to as "choroid") fragments were isolated without retinal pigment epithelium (RPE) removal by peeling RPE away with forceps and placed in growth factor-reduced Matrigel TM (BD Biosciences, Cat. 354230) seeded in 24 well plates.
- RPE retinal pigment epithelium
- Matrigel ® was used to coat the bottom of 24 well plates without touching the edge of the well.
- the thickness of Matrigel ® was approximately 0.4 mm.
- plates were incubated in a 37°C cell culture incubator without medium for 10 minutes in order for the Matrigel TM to solidify.
- 500 ⁇ L of medium EBM-2/EGM (Lonza) was then added to each well and incubated at 37°C with 5% CO 2 for 48 hr before any treatment.
- cells were treated with different concentrations of CeO 2 NP-(C) of formula (I) from 0.05 to 500 ⁇ M of cerium oxide for 7 days. Medium was changed every 48 hr. Images were taken using an Olympus microscope. Microvessels length was quantified using ImageJ software.
- LI-CNV Laser-induced choroidal neovascularization
- the laser-induced choroidal neovascularization (LI-CNV) mouse model has been a crucial mainstay model for neovascular AMD.
- LI-CNV laser-induced choroidal neovascularization
- Ceria-NPs of formula (I) were prepared as indicated above in Materials and Methods.
- TEM image revealed that Ceria-NPs colloids of 3.0-3.5 nm stable in water at concentrations of 1 mg/ml were yielded.
- Cerium oxide nanoparticles are not toxic and reduce intracellular ROS levels in ARPE19 cells:
- CeO 2 NPs-(C) of formula (I) After the synthesis and characterization of CeO 2 NPs-(C) of formula (I), its safety in ARPE19 cells with an MTT assay was evaluated. CeO 2 NPs-(C) of formula (I) incubated during 24 and 48h did not show a reduction in cell viability, at any of the tested concentrations. To test the ability of CeO 2 NPs-(C) of formula (I) to scavenge intracellular ROS in ARPE19 cells, cells were pre-treated with the nanoparticles during 24h, removed the supernatant and adding new media, before exposing them to different oxidant agents for 1h.
- H 2 O 2 , tBH and Antimycin A were used to induce an oxidative stress response in ARPE19 cells through different pathways.
- AA Antimycin A
- Optical microscope images of ganglion cell layer (GCL) slides in the case of exposure to tBH showed the same results with a decrease of fluorescent signal (8-OHdG, fluorescence intensity in arbitrary units (a.u.) ( FIG. 3 (A) ), indicating the presence of free radicals and their decrease as the concentration of CeO 2 NPs-(C) of formula (I) increases.
- CeO 2 NPs-(C) of formula (I) While the treatment with CeO 2 NPs-(C) of formula (I) alone did not produce changes in superoxide dismutase-2 (SOD2) expression, cells treated with CeO 2 NPs-(C) of formula (I) and with induction of oxidative stress experienced a higher increase of SOD2 expression than cells incubated just with tBH ( FIG. 3(B) ). CeO 2 NPs-(C) of formula (I) treatment also induced the upregulation of expression of transcription factor Nrf2 expression ( FIG. 3(C) ). Nrf2 is known as the main antioxidant transcription factor, able to protect cells from oxidative stress by inducing the expression of ROS-neutralizing enzymes (Retinal degenerative diseases, book).
- CeO 2 NPs-(C) of formula (I) Before exploring beneficial therapeutic effects of CeO 2 NPs-(C) of formula (I), two question where addressed. Does the CeO 2 NPs-(C) of formula (I) reach the region of interest after drop casting and does the nanoparticles translocate inside the host. For that, intravitreous vs topical administration were prepared and the Ce contents analysed by Inductively coupled plasma mass spectrometry (ICP-MS) as a function of time and organelle.
- ICP-MS Inductively coupled plasma mass spectrometry
- Biodistribution assays after intravitreal injection were done, and cerium was detected in the retina several weeks after. Cerium was also able to reach the retina (and all posterior segment structures) after a topical administration in a mouse model of dry AMD.
- cerium oxide nanoparticles as a therapy for retina degeneration has been tested in vivo in the tubby and vldlr -/- mice models and in the light-damaged rat model but in all cases, through an intravitreal administration. Given the associated complications this route of administration presents, a topical administration rises as a better option.
- cerium was homogenously distributed in the different parts of the eye, detecting a 2.1% in the retina.
- cerium was preferentially retained in the retina (21.6%), although it was present in all the eye components.
- the anterior pole retained a 14% of all cerium administered in the vitreous cavity. Indeed, the distribution is more homogeneous by eye-drops, avoiding damaging the eye with the puncture.
- the humorous vitreous is a gel highly hydrophilic with 10 nm porosity and negatively charged. Therefore, highly soluble (light and charged), small size and strictly no aggregation is needed for the topical ophthalmological application of the nanoparticles.
- Table 1 shows the results of the distribution assay from a concentration of colloid CeO 2 NPs-(C) of formula (I) at 10 mM (2 mg/ml of cerium oxide) in the aqueous suspension with citrate: Table 1: Distribution of CeO 2 NPs-(C) of formula (I) (percentage %), detected by ICP-MS in different parts of eye 24 h after intravitreal or topical administration. Administration Ant. pole Lens Retina Post. pole Total 24h IV injection (2 ⁇ g) 14% 9,8% 21,6% 11,4% 56,8% Topical (8,6 ⁇ g) 1,7% 2,3% 2,1% 2,1% 8,2%
- Cerium is not excessively accumulated after a one-week daily topical administration:
- CeO 2 NPs-(C) of formula (I) was daily administered at a concentration of cerium oxide of 10mM for one week. After a week, the cerium concentration in the retina was the same achieved with a single intravitreal injection.
- cerium concentration ng/mg tissue
- ICP-MS ICP-MS is depicted for the different parts of eye. Left column in each set of bars indicates amount detected 24h after topical administration (8.6 ⁇ g).
- Ant. Pole means anterior pole including cornea and iris.
- Post. pole means posterior pole or segment of eye including retinal pigment epithelium, sclera and choroid).
- Cerium accumulated in all parts of the eye at a higher concentration that with intravitreal injection (where the sample remained at the injection point probably due to the inflammation consequence of the puncture), preferentially in the posterior pole. Overall, the amount of cerium detected after a one-week administration was much lower than all cerium administered (6.48 ⁇ 1.5 % of total cerium administered; n 4), indicating a high clearance rate.
- aqueous colloidal suspensions of nanoparticles of formula (I) topically administered on the surface of eye i.e. cornea, conjunctiva, etc.
- aqueous colloidal suspensions of nanoparticles of formula (I) topically administered on the surface of eye i.e. cornea, conjunctiva, etc.
- CeO 2 NPs-(C) of formula (I) did not accumulate in liver or brain at any toxic concentration.
- cerium oxide nanoparticles does not cause cytotoxicity (one-week administration):
- CeO2NP treatment inhibits aberrant angiogenesis in vitro and in vivo:
- CeO 2 NPs-(C) of formula (I) were examined using mouse choroidal sprouting assay. Choroids treated with increased concentrations of CeO 2 NPs-(C) of formula (I) showed a reduction in newly formed micro-vessels length compared with choroids treated with VEGF (vascular endothelial growth factor). While VEGF promotes microvasculature to grow, CeO 2 NPs-(C) of formula (I) inhibited choroid sprouting in a dose-dependent manner and better than the control (-VEGF). Data are depicted in FIG. 4 , wherein micro-vessel length in micrograms is illustrated for each tested concentration and compound. Olympus microscope pictures allow also visualizing the reduction in aberrant angiogenesis by CeO 2 NPs-(C) of formula (I).
- Inventors also carried out an assay with a synthetic vitreous humour to see the distribution of the nanoparticles of the invention (CeO 2 NPs-(C)) all along the liquid volume.
- This distribution was compared with that of another colloidal suspension including state of the art ceria nanoparticles stabilized with TMAOH (CeO 2 NP-TMAOH).
- CeO 2 NP-TMAOH state of the art ceria nanoparticles stabilized with TMAOH
- the synthetic vitreous humour (added in a tube) was not as dense as the vitreous humour of mammals, but it served for the purpose of a first approach to see how different ceria nanoparticle (that of the invention and other with aggregates) diffuse all along the different levels of the said vitreous humour.
- Results can be seen in FIG. 6 , where the percentage of concentration of CeO 2 NP distributed along the different levels (upper U, middle M or lower L) of the synthetic vitreous humor are shown in bars. CeO 2 NP were added at the upper level (as shown in figure).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Present invention relates to colloidal suspension of single crystal cerium oxide nanoparticles for use in the treatment of a disorder or disease of the posterior segment of the eye, said treatment comprising administration of a topical ophthalmic dose of the colloidal suspension. Invention also includes particular new eye drop suspensions.
Description
- The present invention relates to the field of medical approaches for ocular diseases of posterior segment of the eye. The invention also relates to ophthalmic compositions.
- Eye is a very complex organ with different specialized cells and tissues. Local and systemic diseases may affect the different regions of the eye, but the anatomy of the eye and complex physiology of the retina and optic nerve makes challenging the development of efficacious drugs.
- Eye is divided into two compartments called the anterior segment (front of the eye) and posterior segment (back of the eye). The anterior segment of the eye refers to the cornea, conjunctiva, anterior sclera (part of sclera that transitions anteriorly to become cornea at the limbus) iris, ciliary body, aqueous humour and the lens. The posterior segment of the eye (also named posterior eye segment) includes the anterior hyaloid membrane and the structures behind this membrane, posterior sclera (part of sclera that transitions posteriorly into optic nerve dural sheet), the vitreous body (including vitreous humour and membrane), retina, macula, choroid and optic nerve. Posterior segment represents the two-thirds of the eye. The leading causes of vision impairment and irreversible blindness are diseases related with the posterior segment of the eye.
- Topical formulations (e.g., eye drops) are the least invasive route for ocular drug administration. Topical local administration is the main modality treatment for anterior segment disease. However, ocular barriers for avoiding pathogens to access also hinder drug delivery even to the anterior segment. In addition, blinking and tear film turnover, designed to wash away foreign material and maintain a smooth clear anterior surface, also limits residence time of a drug. Furthermore, access to posterior segment is hindered by a closely packed corneal epithelium and stroma with varying lipophilicity (see Awwad et al., "Principles of Pharmacology in the Eye", British Journal of Pharmacology-2017, vol no. 174 Issue 23, pp.:4205-4223). Further, the direction of aqueous flow in the eye (ciliary body to anterior chamber angle) is against direction of drug delivery via a topical route.
- Even in case a drug can reach the posterior segment of the eye, it may be removed from the vitreous cavity through diffusion into the anterior chamber, or by the blood-retinal barrier. All this makes difficult any eye treatment of a disease of the posterior segment by topically administration onto eye surface, and the only local modalities in everyday use for treating diseases of the posterior segment of the eye are intravitreal injection (IVT), laser photocoagulation or periocular injections. This is mainly due because is generally assumed that topical administrations do not reach the posterior segment of the eye (ie. the vitreous and the retina), as declared in Urtti A et al., "Challenges and obstacles of ocular pharmacokinetics and drug delivery". Adv. Drug. Deliv. Rev. 2006, vol. 58, pp. 1131-1135. IVT injections avoid all barriers and results in the greatest bioavailability. However, IVT injections imply several severe side-effects, such as retinal detachment. In addition, this kind of intervention is totally senseless at early stages of many of the disease of posterior segment of eye.
- Main posterior segment ophthalmic disorders include pathological neovascularization and ectopic proliferation, atrophy and nerve cell death, inflammation and infection, and detachment. Diseases and conditions commonly associated with these symptoms include macular degeneration (i.e. age-related macular degeneration), diabetic retinopathy, retinopathy of prematurity, retinitis pigmentosa, macular edema, glaucoma, posterior uveitis, endophthalmitis, ocular insult and ocular manifestation of systemic disease such as viral infection, arthritis and rosacea.
- Many of these diseases develop through different stages with different symptoms and gravity. At certain early stages of the development of the disease, an aggressive treatment is not recommended, and patients are simply followed-on and/or they receive certain vitamins and antioxidants usually orally (or systemic or by any other route in other occasions) to slow progression of disease, in part caused by oxidative stress. However, more specific treatments conceived for these diseases at these early stages would deprive the patient of advanced lesions.
- This is the particular case of aged-related macular degeneration (abbreviated AMD). In this disease, retinal cell death occurs due to an increase of oxidative stress and inflammatory response. AMD is a neurodegenerative and complex disorder with multifactorial etiology affecting retina and that results in the progressive and irreversible loss of central vision. AMD is one of the major causes of blindness, together with diabetic retinopathy. AMD is a disease currently unavoidable that represents a major cause of blindness in people over 50 and affects millions of people worldwide. Moreover, it is a disease orphan of treatment. At early stages no specific treatment is administered, rather than vitamins and antioxidants, as previously indicated. At advanced stages of the disease, AMD is classified in two types: wet AMD and dry AMD. The wet form of macular degeneration is related to abnormal growth of blood vessels in the retina that can leak blood and can cause damage to photoreceptor cells and retinal detachment. Approved drugs for advanced stages of wet AMD include certain antibodies such as bevacizumab and ranibizumab intravitreal injections, which are aimed to slow progression of disease. In dry AMD, characterized by a massive atrophy of retinal cells in the macula, no specific treatment has been found effective and finally approved.
- A similar situation can be observed, precisely, with diabetic retinopathy (abbreviated DR), the most common complication of diabetes and that remains the leading cause of blindness among working-age individuals in developed countries. At early stages of DR, neurodegeneration takes place although it is considered a microcirculatory disease (see Simó et al. on behalf of the European Consortium for Early Treatment of Diabetic Retinopathy (EUROCONDOR). "Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications", Br. J. Ophthalmol. - 2012, vol. 96, pp. 1285-1290).
- This state of "orphan of treatment" for all these diseases of the posterior segment is challenging. First, because the systemic administration of antioxidants finds as drawback the difficulty of reaching the target (i.e., posterior segment) due to the natural blood retinal barrier in eye. Thus, it is usually difficult to slow progression of disease. Second, in advanced stages when intravitreal injections are already administered, they suppose expensive treatments besides the dangerous side-effects associated, and on many occasions (very) poor patient compliance (i.e., people stop going to the doctor and interrupt the treatment because they hate to have injections in their eyes and because it also slows down a bit the degeneration while increasing pain and risks).
- About possible drugs to treat disorders or diseases of the posterior segment, cerium oxide nanoparticles (ceria nanoparticles or Ceria NPs) have been disclosed for intravitreal injections to treat glaucoma, age-related macular degeneration (dry and wet forms) and diabetic retinopathy, among other diseases. Thus, in US patent
US7347987B2 administration of ceria nanoparticles to inhibit reactive oxygen species (ROS) and promote longevity of retinal neurons is disclosed. Data are performed in rats to which an intravitreal injection of ceria nanoparticles of unknown diameter size and three-dimensional form was administered. Ultrafine particles are mentioned from 1 to 10 nm, and topical application is also mentioned, although no data are provided. - Another document disclosing the use of ceria nanoparticles to reduce, inhibit or reverse the rate of neovascularization or retinal cell degeneration in diseases of posterior segment of the eye in the US patent application with publication number
US2011111007 . An in vivo assay (Example 2) with a mouse model of AMD is disclosed by administering ceria nanoparticles of unknown size by intravitreal injection.US2011111007 generically disclose ceria nanoparticles with sizes from 1 to 10 nm. Topical application is mentioned, although no data are provided. - Although the documents propose topical application as general mode of administration, no examples are disclosed precisely because it is not the habitual route of administration of drugs to posterior segment.
- Indeed, according to recent prior art, new challenges should also be achieved to translate the use of Ceria nanoparticles to clinical practice and improve patients' treatment in the ophthalmic field: the development of water-soluble ceria nanoparticles; and the development of more permeable ceria nanoparticles to the ocular surface to administer them by a less invasive route of administration, rather than intravitreal injections (see Maccarone et al., 2019. Ophtalmic Applications of Cerium Oxide Nanoparticles. Nanoceria in ophthalmology). In order to improve solubility and permeability, functionalization of particles with saccharides is proposed. To increase corneal permeation, although nanosize can facilitate it, PEGylation and liposome transport are proposed, to avoid nanoparticle aggregation and dramatic size increase. Noteworthy is the fact that ultrafine (1-10 nm) ceria nanoparticles tend to aggregate and to form insoluble clusters that cause severe side-effect, such as immune reactions. Thus, independently of the fact that neither
US7347987B2 norUS2011111007 shows a topic ophthalmic treatment with any ceria nanoparticles, following author's works and the state of the art, the proposed ultrafine sizes would imply aggregation and solubility problems that would cause adverse effects. This is, moreover, challenging with the majority of current available ceria nanoparticles, that are in the form of discrete aggregates of few tens of nanometers in the best cases, and the most often with a cationic surface charge, since the vitreous humour has porosity of about 10 nanometers made of an anionic mesh, in such a way that cationic and larger nanoparticles get absorbed onto it. So, they have to be forced inside the eye. In addition, what can show beneficial work in acute conditions could not be directly translated for the chronic inflammation associated with the advanced stages of these diseases of the posterior segment of the eye, such as AMD. - Thus, there is still a need in the field of effective treatments for all these diseases of ocular posterior segment with low side effects and to face initial stages of some of the diseases when intravitreal injections are not conceivable.
- The inventors have found that certain cerium oxide nanoparticles (abbreviated Ceria NPs) that do not aggregate and are in colloidal suspension in an aqueous media comprising a citrate salt, could be applied topically in the eye (i.e., in the cornea or conjunctival fornix or sclera, that is, ophthalmic application to surface of the eye), and they reached the posterior segment of the eye. Ceria NPs homogeneously distributed in the different parts of the eye (anterior segment, lens, retina). This was achieved with the Ceria NPs with adsorbed citrate in their surface or with citrate as coating, without the need of any functionalization with saccharides, PEG, PVP, EDTA or other for the avoidance of aggregation (i.e., avoidance of precipitation to promote "solubilization" or "homogenous suspension"). Moreover, permeation through the several parts of the anterior segment was accomplished without any nanoparticle surface covalent modification by means of hydrophobic or amphiphilic molecules (i.e., PEGylation), or without the need of encapsulating Ceria NPs into supramolecular structures (i.e., liposomes) containing lipids or hydrophobic or amphiphilic polymeric compounds.
- Therefore, inventors have surprisingly found a mode to maintain Ceria NPs of low diameter in colloidal suspension that do not aggregate. The nanoparticles were, thus, isolated single nanoparticles in suspension and monodispersed (i.e., >90% of uniformity in size distribution). These particular suspensions could enter the posterior segment from the anterior segment and no particle aggregation was observed, thus avoiding any secondary effect due to the formation of the precipitates.
- Moreover, as will be depicted in examples below, the amount of Ceria NPs that reached the posterior segment (retina and different parts of posterior pole) was about 30-50 % of the amount that was finally detected in the several eye parts after being topically administered. These detected amounts achieved effective concentrations for abrogating the evolution of the diseases. Advantageously, no toxicity was observed in tissues where Ceria NPs were retained, and they were neither detected in liver nor in brain. In addition, as will be illustrated in examples below, the concentration reached in the different parts with topical administration was about half of the reached with intravitreal injection. These were therapeutically effective amounts and, thus, for the first time Ceria NPs could be used as an actual substitute of intravitreal injections for the treatment of disorders, conditions or diseases of the ocular posterior segment.
- Yet another advantage of the proposed Ceria NPs and related with the toxicity is that, according to preliminary results, the particles do not accumulate in the eye in case of overdose and any excess is quickly removed/rinsed away. This makes possible repeated administration schedules for more than one day (i.e., 7 days or more), since after seven days of application of the Ceria NPs in form of a collyrium, only a 4-fold increase of concentration was observed with indications of saturation.
- Thus, in a first aspect the invention relates to a single-crystal single cerium oxide nanoparticle of formula (I):
NP-(C) (I),
wherein
NP is a single-crystal single cerium oxide (CeO2) nanoparticle with a crystal diameter from 3 to 5 nm, and (C) is a coating of citrate molecules adsorbed on the NP,
for use in the treatment of a disorder or disease of the posterior segment of the eye, wherein the treatment comprises administration of a topical ophthalmic dose of single-crystal single cerium oxide nanoparticles of formula (I). - This aspect of the invention can also be formulated as the use of a single-crystal single cerium oxide nanoparticles of formula (I) for the manufacture of a medicament for the prevention and/or treatment of a disorder or disease of the posterior segment of the eye, wherein the prevention or treatment comprises administration of a topical ophthalmic dose of these nanoparticles of formula (I). The present invention also relates to a method for the topical eye (ophthalmic) treatment and/or prevention of a disorder or disease of the posterior segment of the eye, comprising administering (meaning topically administering in the eye) a topical ophthalmic dose of nanoparticles of formula (I), together with topical pharmaceutically or veterinary acceptable excipients and/or carriers, in a subject in need thereof, including a human.
- The nanoparticles of formula (I) are referred along this description as coated Ceria-NP, coated CeO2-NP, CeO2-NP-(C), or simply NP-(C). In any case, and if not indicated to the contrary, they relate to the nanoparticles of the single-crystal oxide comprising the citrate molecules associated to or adsorbed or coating (used as synonymous) said single-crystal.
- For this topical ophthalmic administration, the nanoparticles are particularly in form of an aqueous colloidal suspension comprising the single-crystal single cerium oxide nanoparticles of formula (I) (NPs-(C)) of formula (I)), and a pharmaceutically acceptable citrate salt.
- Thus, another aspect of the invention relates to aqueous colloidal suspensions comprising a pharmaceutically acceptable citrate salt and nanoparticles of formula NP-(C) (I),
wherein NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, and (C) is citrate adsorbed on, thus coating, the NP; being these suspensions for use in the treatment of a disorder or disease of the posterior segment of the eye, wherein the treatment comprises administration of a topical ophthalmic dose of the aqueous colloidal suspension. - These colloidal suspensions for the intended use are obtainable by preparing CeO2 nanoparticles using a cerium (III) citrate complex as a precursor and the pH basic precipitation in the presence of an excess of the pharmaceutically acceptable citrate salt, this excess defined as an amount higher than the one needed to fully cover the CeO2 nanoparticle available surface. Inventors have determined that for 1 mg/ml of CeO2 nanoparticles the amount in excess of the pharmaceutically acceptable salt of citrate in the colloidal suspension is from 2 to 10 mM in order to have a stable active principle that is further dispersed, for example, in a methylcellulose solution or other cellulose polymers (see examples below where citrate coated CeO2NPs of formula (I), were dispersed into a solution containing 5% of methylcellulose to get a CeO2 final concentration of 2 mg/ml of CeO2).
- Thus, it is also herewith disclosed an aqueous colloidal suspension comprising a pharmaceutically acceptable citrate salt and nanoparticles of formula NP-(C) (I), obtainable by:
- (i) mixing in an aqueous medium a salt of cerium, in particular cerium nitrate, with an amount of a pharmaceutically acceptable citrate salt, in particular a citrate salt of an alkali or alkaline-earth element and which amount of citrate salt is in excess in relation to the amount of the salt of cerium, and let the reaction mixture under stirring for an adequate time, while media is conducted at a basic pH, to get cerium (III) complexes with citrate be oxidized to cerium (IV) complexes before mineralization, that is, before the formation of the cerium oxide;
- (ii) allowing the reaction mixture to reflux at a temperature of at least100 °C for a period of time to obtain a suspension with dispersed CeO2 nanoparticles (NP), which are single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, and that comprise citrate (C) adsorbed on, thus coating, the NP.
- Note that in absence of the citrate salt, such as sodium citrate (SC), Cerium nitrate will precipitate in form of cerium oxide at RT (room Temperature) and basic pH, forming aggregates. However, the stability of the cerium bond with the salt of citrate (e.g., Ce-SC bond) prevents this, and high temperature (T) for a period of time is needed then to break the complex bonds and to obtain the CeO2 NPs (mineral) coated with the citrate salt (i.e., SC coated CeO2 NPs).
- The colloidal suspensions of Ceria NPs of formula (I) include these nanoparticles as single-crystals (i.e. no aggregation of particles but isolated) with a diameter allowing the entering to the ocular posterior segment without precipitation in the aqueous suspension, in part due to the presence of the citrate molecules adsorbed on the single-crystal, or in other words making a kind of coating around it. Citrate molecules are associated by ionic or van der Waals forces with the cerium oxide surface of the nanoparticles, which acquire a net negative charge. Thus, colloidal particles are negatively charged. Despite the low size of the particles, therapeutic amounts surprisingly entered and reached retina without the aid of nanoparticle functionalization. Thus, in the aqueous colloidal suspension the nanoparticles surface is free of any functionalization by molecules of hydrophobic or amphiphilic nature (i.e., polyethylene glycols, saccharides) and free of encapsulating carriers (i.e., liposomes, exosomes, etc.). Avoidance of functionalization is of interest, since the more complex the molecules, the more reactive generally to immune system of the host.
- Considering the state of the art, it was unexpected that so simpler (without functionalization) nanoparticles of a very small size did not aggregate and did reach retina and other posterior segment parts of eye once applied topically onto the eye surface.
- This second aspect of the invention can also be formulated as the use of aqueous colloidal suspensions comprising single-crystal single cerium oxide nanoparticles of formula (I) as defined above (i.e. NP-(C)), and a pharmaceutically acceptable citrate salt, for the manufacture of a medicament for the prevention and/or treatment of a disorder or disease of the posterior segment of the eye, wherein the prevention or treatment comprises administration of a topical ophthalmic dose of these aqueous colloidal suspensions. The present invention also relates to a method for the topical eye (ophthalmic) treatment and/or prevention of a disorder or disease of the posterior segment of the eye, comprising administering (meaning topically administering in the eye) a topical ophthalmic dose of an aqueous colloidal suspension comprising single-crystal single cerium oxide nanoparticles of formula (I) (i.e. NP-(C)) as defined above, and a pharmaceutically acceptable citrate salt, together with topical pharmaceutically or veterinary acceptable excipients and/or carriers, in a subject in need thereof, including a human.
- A third aspect of the invention is a pharmaceutical or veterinary composition comprising:
- (a) single-crystal single cerium oxide nanoparticles of formula (I):
NP-(C) (I),
- NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, measured with transmission electron microscopy and X-Ray diffraction, and (C) is citrate molecules adsorbed on, thus coating, the NP; and (b) a pharmaceutically or veterinary acceptable citrate salt, together with pharmaceutically or veterinary acceptable excipients and/or carriers.
- These compositions, when formulated in particular as pharmaceutical or veterinary topical eye colloidal suspensions comprising the nanoparticles in colloidal suspension and the pharmaceutically or veterinary acceptable citrate salt, allow high penetration percentages of the active into the posterior segment, and a uniform distribution within all the structures therein, although topically applied (i.e., through cornea, sclera or conjunctiva).
-
-
FIG. 1 is a graphic of bars with cerium concentration (ng/mg tissue), detected by ICP-MS (Y- axis) in the different parts of eye (X-axis), after intravitreal (black bars) or topical administration (pattern bars). Ant. Pole means anterior pole including cornea and iris. Post. pole means posterior pole or segment of eye including retinal pigment epithelium, sclera and choroid). -
FIG. 2 is also a graphic of bars with cerium concentration (ng/mg tissue), detected by ICP-MS (Y-axis) in the different parts of eye (X-axis). Left column in each set of bars indicates amount detected 24h after topical administration (8.6 µg). Column in the middle of each set of bars indicates amount detected 7 days (7d) after a daily topical administration (60.2 µg in a week; 8.6 µg/day). Right bar of each set of bars indicates amount detected 24 h after intravitreal administration (2 µg). Ant. Pole means anterior pole including cornea and iris. Post. pole means posterior pole or segment of eye including retinal pigment epithelium, sclera and choroid). -
FIG. 3 is a graphic showing for 8-OHdG, fluorescence intensity in arbitrary units (a.u.) detected in an assay with vehicle (fresh cell culture media) and the aqueous colloidal suspension comprising citrate coated CeO2NPs (i.e. NP-(C)) (FIG. 3(A)). FIG. 3(B) and FIG. 3(C) show mRNA relative levels SOD2 and Nrf2 expression, respectively. -
FIG. 4 illustrates angiogenesis (microvessel length (L) in micrometers) tested for different concentrations of CeO2NP-(C) of formula (I) from 0.05 to 500 µM of CeO2 for 7 days in a choroid sprouting assay. Medium was changed every 48 hr. Images were taken using an Olympus microscope. Microvessels length was quantified using ImageJ software. VEGF is the positive control. -
FIG. 5 is a graphic that shows anti-angiogenic activity of CeO2NP-(C) of formula (I) in an in vivo mouse model of choroidal neovascularization induced by laser. Area is the area of lesion. -
FIG. 6 shows the percentage concentration of CeO2NP distributed along a synthetic vitreous humor. CeO2NP-TMAOH corresponds to an aqueous suspension comprising state of the art nanoparticles prepared with tetramethylamoniun hydroxide and that do not contain citrate molecules. CeO2NP-(C) corresponds to an aqueous suspension of ceria nanoparticles according to the invention prepared in the presence of sodium citrate. Each bar illustrates the concentration of cerium measured at the different levels (upper U, middle M or lower L) of the simulated (i.e., synthetic) vitreous humor. -
FIG.7 shows the Dynamic Light Scattering (DLS) analysis of the nanoparticles for use in the invention. It displays the peaks of the size distribution (Size in nm) by intensity (I %). DLS showed a well-defined peak by intensity around 5 nm which corresponds to single dispersed CeO2 NPs. Other less intense peaks at 100's of nm were sometimes observed. These large peaks appeared even after filtering the sample with a 300 kDa (10 nm) cellulose filter, thus inventors consider that they are artifacts due to the low scattering of these ultrasmall nanoparticles. Further corroboration of this is the fact that after filtering the solution with a 10 nm pore filter, most of the absorbance of the particles was preserved. This peak disappears when the data is visualized by number rather than intensity. The picture illustrates three records with nanoparticles obtained withCe 10 mM andsodium citrate 20 mM with TMAOH at 25 mM and filtered. - All terms as used herein in this application, unless otherwise stated, shall be understood in their ordinary meaning as known in the art. Other more specific definitions for certain terms as used in the present application are as set forth below and are intended to apply uniformly through-out the specification and claims unless an otherwise expressly set out definition provides a broader definition.
- As used herein, the indefinite articles "a" and "an" are synonymous with "at least one" or "one or more." Unless indicated otherwise, definite articles used herein, such as "the" also include the plural of the noun.
- By "single-crystal single cerium oxide nanoparticle" it is to be understood that said nanoparticle is not aggregated (by weak or strong physical interaction) with other nanoparticles. Thus, it is isolated as a mono-nanoparticle or monodispersed. They are also termed "single crystallites of cerium oxide". For example, single 3-5 nm crystallites of cerium oxide. All these structures can be seen by TEM. With the TEM technology high electron density of the Cerium atoms coupled to oxygen can be visualized. With X-ray technology crystal domains (group of atoms in columns and rows in the same crystal structure) are detected. According to this description, single-crystal or monocrystal means that there is only one crystal of cerium oxide configuring the nanoparticle, which has a particular crystal diameter. Being said nanoparticles single nanoparticles and single-crystal, the X-ray diffraction detected crystal domain is highly similar with the diameter detected by TEM, which is the prove that nanoparticles are not aggregated, as DLS measurements corroborate (
FIG.7 ). - The term "nanoparticle" as used herein, refers generally to a particle with at least two dimensions at the nanoscale, particularly with all three dimensions at the nanoscale (1-100 nm). In this description, the nanoparticles are in the range about 3 nm to about 5 nm, including 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9 and 5. More particularly in the range from 3.0 to 3.5 nm. As regards the shape of the nanoparticles described herein, there are included spheres and polyhedral. In a particular embodiment the nanoparticle is spherical.
- As used herein, the term "size" refers to a characteristic physical dimension. For example, in the case of a nanoparticle that is substantially spherical, the size of the nanoparticle corresponds to the diameter of the nanoparticle. When referring to a set of nanoparticles as being of a particular size, it is contemplated that the set of nanoparticles can have a distribution of sizes around the specified size. Thus, as used herein, a size of a set of nanoparticles can refer to a mode of a distribution of sizes, such as a peak size of the distribution of sizes. In addition, when not perfectly spherical, the diameter is the equivalent diameter of the spherical body including the object.
- The term "cerium oxide" or "ceria" refers to cerium (III) oxide (Ce3+) and cerium (IV) oxide (Ce4+) species that are both present when constituting the nanoparticles. Although many of the cerium atoms in cerium oxide nanoparticles are usually in the (Ce4+) oxidation state, small cerium oxide nanoparticles also contain cerium atoms in the (Ce3+) oxidation state. Cerium oxide nanoparticles (abbreviated also as Ceria NPs, CeO2-NP or simply CNP) are used in a variety of applications mainly due to its high surface area and the ability of cerium oxide to cycle between (III and IV) oxidation states. In a particular embodiment, cerium oxide nanoparticles are in the (Ce4+) oxidation state.
- When in this description the diameter of the nanoparticle is mentioned, it relates to the crystal size diameter (single crystal). As previously indicated, crystal size is usually measured from X-ray diffraction patterns while particle size is measured by TEM. In the case of single-crystal nanoparticles, XRD, TEM and DLS sizes coincide. Typical crystal size diameters of the nanoparticles used in the present invention range from 3 to 5 nm, when measured by TEM, more particularly the crystal size diameter of the nanoparticles is about 5 nm.
- The "hydrodynamic diameter" determined by dynamic light scattering (DLS) techniques based on the Stoke-Einstein equation is used herewith to refer to the single-crystal nanoparticle with adsorbed water and other molecules in the colloidal suspension. It can be measured by illuminating the particles with a laser and analyzing the intensity fluctuations in the scattered light. Dynamic light scattering measures Brownian motion and relates it to the size of the particles for which light intensity is proportional to the square of the volume of the particle. Therefore, the hydrodynamic size is always larger than the size observed by transmission electron microscopy, this later the one of the single-crystal nanoparticles. Typical hydrodynamic diameters of the single-crystal cerium oxide nanoparticles for use in present invention (highly monodispersed nanoparticles) gave a peak around 5 nm, which was much the same as TEM and XRD)
- In chemistry, a colloid is a mixture in which one substance of microscopically dispersed insoluble particles is suspended throughout another substance. Sometimes the dispersed substance alone is called the colloid; the term colloidal suspension refers unambiguously to the overall mixture. Unlike a solution, whose solute and solvent constitute only one phase, a colloid has a dispersed phase (the suspended particles) and a continuous phase (the medium of suspension) that arise by phase separation. To qualify as a colloid, the mixture must be one that does not settle or would take a very long time to settle appreciably. In case of this invention, the dispersed phase are the single-crystals of single Ceria NPs (3-5 nm) with the associated citrate (C) molecules (citrate coating) on their surface, and the continuous phase where particles are suspended is a solvent, preferably a polar solvent (i.e. water, optionally buffered) comprising also the pharmaceutically acceptable citrate salts (in excess).
- The expression "therapeutically effective amount" as used herein, refers to the amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disease which is addressed. The particular dose of compound administered according to this invention will of course be determined by the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated, and the similar considerations.
- The term "pharmaceutically or veterinary acceptable" as used herein pertains to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical and veterinary judgment, suitable for use in contact with the tissues of a subject (e.g. human or any other animal) without significant toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, excipient, etc., must also be "acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical composition. It must also be suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications commensurate with a reasonable benefit/risk ratio. Suitable carriers, excipients, etc. can be found in standard pharmaceutical texts, and include, as a way of example preservatives, agglutinants, humectants, emollients, tonicity agents to adjust osmolality, chelating agents, and antioxidants.
- As above exposed, the inventors propose a new therapeutically approach for disorders, conditions or diseases of the posterior segment of the eye.
- According to the first aspect, single-crystal single cerium oxide nanoparticles of formula (I):
NP-(C) (I),
wherein - NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, and (C) is a coating of citrate molecules adsorbed on the NP, are proposed for use in the treatment of a disorder or disease of the posterior segment of the eye, wherein the treatment comprises administration of a topical ophthalmic dose of aqueous colloidal suspension.
- In a particular embodiment of the first aspect, the single-crystal single cerium oxide nanoparticles have a crystal diameter from 3 to 3.5 nm measured by TEM. This means that the single-crystal single cerium oxide nanoparticles have a crystal diameter selected from 3.0, 3.1, 3.2, 3.3, 3.4, 3.5 nm, as the mean of crystal diameter of the distribution of sizes.
- The second aspect of the invention relates to aqueous colloidal suspensions comprising a pharmaceutically acceptable citrate salt and nanoparticles of formula NP-(C) (I),
wherein NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, and (C) is citrate adsorbed on, thus coating, the NP; being these suspensions for use in the treatment of a disorder or disease of the posterior segment of the eye, wherein the treatment comprises administration of a topical ophthalmic dose of aqueous colloidal suspension. - In a particular embodiment of these aqueous colloidal suspensions for use according to this second aspect, the single crystal single cerium oxide nanoparticles have a crystal diameter from 3 to 3.5 nm measured by TEM. This means that the single crystal cerium oxide nanoparticles have a crystal diameter selected from 3.0, 3.1, 3.2, 3.3, 3.4, 3.5 nm, as the mean of crystal diameter of the distribution of sizes.
- In another particular embodiment of the aqueous colloidal suspensions, for use as indicated, optionally in combination with any of the embodiments above or below, the pharmaceutically acceptable citrate salt in the colloidal suspension is selected from an alkaline and an alkaline-earth metal salt, or combinations thereof. Thus, in a more particular embodiment it is selected from a pharmaceutically acceptable lithium citrate, sodium citrate, potassium citrate, beryllium citrate, magnesium citrate, calcium citrate, strontium citrate, barium citrate and radium citrate. In a more particular embodiment is sodium citrate.
- Aqueous colloidal suspensions for use according to the second aspect comprise, in a particular embodiment, the pharmaceutically acceptable citrate salt at a final concentration from 1.0 to 20 mM. More in particular, from 2.0 to 10 mM.
- Inventors tested several concentrations of the nanoparticles of formula (I) in the aqueous colloidal suspension in an in vivo model. Doses of the topical ophthalmic route could be adjusted from 1.0 to 250 micrograms of the CeO2 in the form of the nanoparticles of formula (I) per day (micrograms/eye/day). These doses include very low, but effective doses. This supposes the advantage of null side-effects while effectivity is maintained, precisely due to the "catalytic behavior" of ceria. Moreover, final pharmaceutical composition can be afforded for an appropriate cost to consumer.
- Doses and concentrations of the nanoparticles of formula (I) in this description are indicated using the administered amount in micrograms/eye/day of cerium oxide (which is in the form of the citrated coated nanoparticles), or the concentration of this cerium oxide in the administered composition (in mg/ml or in the equivalent molarity according to cerium oxide molecular weight; 172.11 g/ml). For the quantification of cerium oxide in any of its oxidation states there are spectrophotometric and mass spectroscopy techniques the skilled person in the art will know.
- The aqueous colloidal suspension for use according to this aspect of the invention is, in a particular embodiment, an eye drop colloidal suspension. This means that the colloidal suspension comprising the ceria NPs of formula (I) and the pharmaceutically acceptable citrate salt, also includes excipients and carriers, such as buffer systems and preservatives. The pharmaceutical or veterinary topical eye drop colloidal suspension are to be understood as topical eye compositions applicable to the cornea, sclera or to the conjunctival fornix.
- As indicated, particular ophthalmic doses of cerium oxide administered in this form of nanoparticles of formula (I) in the aqueous suspensions are from 1.0 to 250.0 micrograms of cerium oxide/day (i.e., micrograms/eye/day). In a more particular embodiment, the ophthalmic doses are from 1.0 to 100.0 micrograms/day. In another more particular embodiment, they are from 2.0 to 50.0 micrograms/day, even more in particular from 5.0 to 50.0 micrograms/day. When these aqueous colloidal suspensions are in form of eye drops they are generally used in volumes of 30 to 50 microliters/drop, more in particular 50 microliters/drop. These doses can be applied once a day or more than once a day. They can also be maintained for one or several weeks.
- More in particular the ophthalmic dose of cerium oxide is administered from an aqueous colloidal suspension comprising from 1.0 to 5.0 mg/ml, more in particular from 2.0 to 4.0 mg/ml of cerium oxide as the single-crystal single cerium oxide nanoparticles of formula (I), stabilized in the excess of the pharmaceutical citrate salt. Thus, in the aqueous colloidal suspension comprising the single-crystal single cerium oxide nanoparticles of formula (I), cerium oxide is at a concentration selected from 1.0, 2.0, 3.0, 4.0, 5.0 mg/ml. These concentrations allow the administering of ophthalmic doses of cerium oxide in the nanoparticle form that range from 50 µg to 250 µg per drop of 50 µl, for example.
- In a more particular embodiment of the aqueous suspension for the proposed use, it comprises 2 mg/ml of the cerium oxide in form of the single-crystal single cerium oxide nanoparticles of formula (I), wherein the crystal diameter of CeO2NPs is of 3.5 nm measured by TEM, and wherein the final ophthalmic dose of the cerium oxide in form of the single-crystal single cerium oxide nanoparticles of formula (I) is from 1.0 to 250 micrograms/eye/day.
- Many are the diseases of the posterior segment of eye. The aim of this invention is to focus on every ocular disease of the posterior segment, in which there is an inconvenient pro-inflammatory state and general oxidative stress, mainly caused by ROS, which damage the structures and worsens the disease, if already manifested, from an acute stage to a chronic stage.
- Thus, in a particular embodiment of the single-crystal single nanoparticle or the aqueous colloidal suspension comprising it, for use as indicated, the eye disease is any disorder of any of the structures or tissues of the posterior segment, in that beside the primary disease cause (genetic, multifactorial, trauma, cancer, ...), inconvenient pro-inflammatory state and general oxidative stress environment is present. This is common to all diseases listed below.
- Thus, in a particular embodiment of the first and second aspects, the single-crystal single nanoparticle and the aqueous colloidal suspension is for use in the prevention and/or treatment of a condition or disease of the posterior segment of the eye selected from the group consisting of retinal and/or choroid pathologies, vitreous humour pathologies, posterior sclera pathology, optic nerve pathologies, intraocular tumors, and combinations thereof.
- In a more particular embodiment, optionally in combination with any embodiment above or below of the single-crystal single nanoparticle or of the colloidal suspension for use of the first and second aspects, the disease of the posterior segment of the eye is a retinal pathology and/or choroid pathology selected from a retinal vasculopathy, a maculopathy, an hereditary eye fundus dystrophy, an idiopathic chorioretinopathy, a central serous retinopathy, generalized choroidal dystrophy, retinoblastoma, and combinations thereof.
- In a more particular embodiment, the single-crystal single nanoparticle or the aqueous colloidal suspension comprising the nanoparticles is for use in the prevention and/or treatment of a retinal vasculopathy selected from diabetic retinopathy, diabetic papillopathy, non-diabetic retinopathy, ocular ischemic syndrome, hypertensive retinopathy, thalassemia retinopathy, Coats' syndrome, Eales' syndrome, radiation retinopathy, solar retinopathy, purtscher retinopathy, polypoidal choroidal vasculopathy (PCV), retinal macroaneurysm, retinal microaneurysm, leukemic retinopathy, retinal ischemia, chronic retina disorders, and combinations thereof. In a more particular embodiment, the single-crystal single nanoparticle or the aqueous colloidal suspension is for use in the prevention and/or treatment of diabetic retinopathy, even more in particular early stages of the disease when intravitreal injections are not adequate due to their associated risks.
- Indeed, as previously indicated, current aqueous colloidal suspensions for the intended use with the nanoparticles of formula (I), or this nanoparticles as such, are real substitutes of intravitreal injections, making them in a particular embodiment for use in early stages of the conditions or diseases listed in this description without any risk for the subject. This is of particular interest for the known as dry form of aged-related macular degeneration (AMD) and for diabetic retinopathy.
- Thus, in another particular embodiment of the first aspect, the single-crystal single nanoparticle, or the aqueous colloidal suspension comprising it is for use in the prevention and/or treatment of a maculopathy selected from aged-related macular degeneration (AMD), retinal angiomatous proliferation, polipoidal choroidal vasculopathy, malattia leventinese, full thickness macular hole, macular epiretinal membrane, macular telangiectasias, cellophane maculopathy or macular pucker, myopia maculopathy, exudative maculopathy after venous thrombosis of the retina, acute macular neuroretinopathy, macular cystoids, macular edema, retinal angioid streaks, choroidal folds, hypotony maculopathy and combinations thereof; and wherein the hereditary eye fundus distrophy is selected from the group consisting of retinitis pigmentosa; atypical retinitis pigmentosa including but not limited to Usher's syndrome, retinitis punctata albicans, Leber's congenital amaurosis, dystrophy of the cones, rod dystrophy, Bietti crystalline corneoretinal dystrophy, juvenile macular dystrophy, all types of macular dystrophy, Stargardt's disease or Fundus flavimaculatus, Usher's Syndrome and combinatios thereof.
- In another more particular embodiment, the single-crystal single cerium oxide nanoparticle of formula (I), or the aqueous colloidal suspension, as above disclosed, is for use in the prevention and/or treatment of AMD selected from wet AMD and dry AMD (geographic atrophy). In a more particular embodiment is for use in dry AMD. In another particular embodiment is for use in the prevention and/or treatment of retinitis pigmentosa.
- In another particular embodiment, the single-crystal single cerium oxide nanoparticle of formula (I), or the aqueous colloidal suspension comprising it, is for use in the prevention and/or treatment of a vitreous humour pathology selected from the group consisting of sub-macular and vitreous haemorrhages, asteroid hyalosis, vitreous detachment, eye floaters or myodesopsia, hereditary vitreoretinopathies, Stickler's syndrome or Wagner's Syndrome, and combinations thereof.
- In also another particular embodiment, the single-crystal single cerium oxide nanoparticle of formula (I), or the aqueous colloidal suspension comprising it, is for use in the prevention and/or treatment of an optic nerve pathology selected from the group consisting of optic atrophy, optic neuritis, neuroretinitis, ischemic neuropathy, hereditary optic neuropathy, toxic amblyopia or nutritional optic neuropathy, ocular hypertension, primary glaucoma , secondary glaucoma, iridocorneal endothelial syndrome associated to glaucoma, head drusen or optic disc drusen, papilledema and combinations thereof. In a more particular embodiment is for use in the prevention and/or treatment of primary glaucoma or secondary glaucoma.
- Inventors have developed particular eye colloidal suspensions to put the proposed use into practice.
- Thus, as previously indicated, another aspect of the invention relates to a pharmaceutical or veterinary composition comprising:
- (a) a therapeutically effective amount of single-crystal single cerium oxide nanoparticles of formula (I):
NP-(C) (I),
wherein
NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, measured with transmission electron microscopy and X-Ray diffraction, and (C) is citrate (i.e., citrate molecules) adsorbed on, thus coating, the NP; and - (b) a pharmaceutically or veterinary acceptable citrate salt, together with pharmaceutically or veterinary acceptable excipients and/or carriers.
- In a particular embodiment of the pharmaceutical or veterinary composition, it is a pharmaceutical or veterinary topical eye colloidal suspension comprising:
- (a) a therapeutically effective amount of single-crystal single cerium oxide nanoparticles of formula (I):
NP-(C) (I),
wherein - NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, measured with transmission electron microscopy and X-Ray diffraction, and (C) is citrate adsorbed on, thus coating, the NP; and (b) a pharmaceutically or veterinary acceptable citrate salt, together with topical ophthalmic pharmaceutically or veterinary acceptable excipients and/or carriers.
- In a more particular embodiment of the pharmaceutical or veterinary topical eye colloidal suspension, it comprises single-crystal single cerium oxide nanoparticle of formula (I) giving an amount in the suspension from 1.0 mg/ml to 5.0 mg/ml of the cerium oxide. More in particular, it comprises single-crystal single cerium oxide nanoparticle of formula (I) giving an amount from 2.0 mg/ml to 4.0 mg/ml of cerium oxide; even more in particular of 2.0 mg/ml).
- In another particular embodiment, the pharmaceutically acceptable citrate salt in the pharmaceutical or veterinary composition, being in particular a pharmaceutical or veterinary topical eye colloidal suspension, is at a final concentration from 1.0 to 20 mM. More in particular, from 2.0 to 10 mM.
- In also another particular embodiment of the topical eye aqueous colloidal suspension, optionally in combination with any of the embodiments above or below of these topical eye aqueous colloidal suspensions, it has a viscosity from 3000-5500 mPa.
- When in this description it is indicated that a composition has a particular viscosity within a range, it is related to the dynamic viscosity. Thus, the pharmaceutical compositions of the invention have a dynamic viscosity from 3000 to 5500mPa, at room temperature (i.e., 20 ±0.1 °C) and normal atmospheric pressure. According to the European pharmacopoeia (8th edition, 2.2.8 "Viscosity"), dynamic viscosity or viscosity coefficient η is the tangential force per unit surface, known as shearing stress T and expressed in pascals, necessary to move, parallel to the sliding plane, a layer of liquid of 1 square meter at a rate (v) of 1 meter per second relative to a parallel layer at a distance (x) of 1 meter. The ratio dv/dx is a speed gradient giving the rate of shear D expressed in reciprocal seconds (s-1), so that η=T/D. The unit of dynamic viscosity is the pascal second (Pa.s).
- In also another particular embodiment of the topical eye aqueous colloidal suspension, optionally in combination with any of the embodiments above or below of these topical eye aqueous colloidal suspensions, it comprises single-crystal single cerium oxide nanoparticles of formula (I) (i.e. citrate coated CeO2NPs) dispersed in a polar solvent, said solvent comprising water, a citrate salt (i.e. sodium citrate), the viscosity agent hydroxypropyl methylcellulose, the preservatives benzalkonium chloride and boric acid, and the tensoactive amino hydroxy methyl propanediol.
- Additionally, the aqueous (i.e., for eye drop) colloidal suspensions of the present invention may contain other ingredients, such as fragrances, colorants, and other components known in the state of the art for use in topical eye formulations.
- Topical eye compositions of the present invention can be prepared according to methods well known in the state of the art. The appropriate excipients and/or carriers, as well as any pH buffer, and their amounts, can readily be determined by those skilled in the art according to the type of formulation being prepared.
- Components in the topical eye (ophthalmic) composition of the invention include, in some particular embodiments, tensoactives, solvents (organic and inorganic solvents; i.e. water), viscosity agents, preservatives, agglutinants, emollients, and antioxidants, isotonifying and/or isoosmozing agents, and mucoadhesive polymers.
- Other viscosity agents are in particular polyvynil alcohol, compounds derived from cellulose such as methylcellulose and hydroxypropylmethylcellulose, carbomers, PEG and mixtures thereof. Other preservatives are in particular, benzoic acid, p-hydroxybenzoic esters of C1-C4-alkyl chains (i.e. methyl-, ethyl-, propyl-, and butyl-p-benzoate), chlorobuthanol, benzyl alcohol, and mixtures thereof.
- Isotonifying and/or isoosmozing agents, are in particular sodium chloride, dextrose, trehalose, mannitol, amino acids and mixtures thereof.
Excipients used as pH buffers are those allowing a pH from 4.5 to 9.0, more in particular from 4.5 to 8.5, even more in particular from 6.0 to 8.2, and preferably from 7.0 to 8.1, even more preferably from 7.5 to 8.0. Examples of pH buffers include citrate salts (citric acid/citrate buffer), which is this case is constituting the aqueous colloidal suspension, phosphate salts (phosporic acid/phosphate buffer), borate salts (boric acid/borate buffer), and mixtures thereof, all salts being those pharmaceuticaly accepatble. pH buffers may in additional comprise amino acids, in particular arginine, lysine, and an amine-derived compound selected from methylglucamine and trometamol, and mixtures thereof. - The pharmaceutical or veterinary composition comprising: (a) a therapeutically effective amount of single-crystal single cerium oxide nanoparticles of formula (I); and (b) a pharmaceutically or veterinary acceptable citrate salt, together with pharmaceutically or veterinary acceptable excipients and/or carriers, are in a particular embodiment in a form selected from solutions, creams, lotions, unguents, emulsions, and suspensions. These particular compositions comprise, in even a more particular embodiment, topical pharmaceutically or veterinary acceptable excipients and/or carriers. More in particular, these topical compositions, in any of the forms, are also conceived for application onto skin and mucosae.
- Throughout the description and claims the word "comprise" and variations of the word, are not intended to exclude other technical features, additives, components, or steps. Furthermore, the word "comprise" encompasses the case of "consisting of". Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples and drawings are provided by way of illustration, and they are not intended to be limiting of the present invention. Furthermore, the present invention covers all possible combinations of particular and preferred embodiments described herein.
- A 50 mL solution of tetramethylamoniun hydroxide (TMAOH) 50 mM was added to a pre-formed 50 mL of a solution containing 20 mM of CeNO3 and 40 mM of sodium citrate (SC) in a 250 mL glass bottle where the Ce-SC complex is spontaneously formed. The reaction mixture was then left under stirring at room temperature overnight. During this time the colour of the solution changed from colourless to brown and finally yellow, which indicated the oxidation of Ce3+ to Ce4+ and the formation of Ce4+-citrate complexes. Later, the reaction mixture was added to a three necked round bottom flask and left under refluxing at 100°C for 4h to break Ce-SC complexes and allow Ce oxide mineralization. During this time, the colour of the solution changed from yellow to pale yellow. This pale-yellow clear solution is in accordance with the typical appearance of well dispersed CeO2NPs. Precipitation was not observed. Thus, an aqueous colloidal suspension comprising CeO2NPs and citrate adsorbed on (or coating) this CeO2NPs was obtained. The nanoparticles were single-crystal single cerium oxide nanoparticles of formula (I) (NP-(C)), as revealed by TEM (see below in Results section), with CeO2NPs colloids of 3.0-3.5 nm diameter stable in water comprising the citrate salt, being part of the citrate associated or adsorbed (i.e. coating) on the single-crystal.
- A solution of
Methocel ® 20% (Omnivision AG, Neuhausen, Switzerland) was used to prepare the CeO2NPs-based eye drops. 1 ml Methocel® contains, according to the manufacturer specifications, 20 mg hydroxypropyl methylcellulose, 0.1 mg benzalkonium chloride, boric acid, amino hydroxy methyl propanediol and water. It has a viscosity of 3000-5500 mPa.s. To prepare the CeO2NPs-based eye drops, theMethocel ® 20% was diluted four times in distilled H2O (thus, hydroxypropyl methylcellulose was at 5% of weight), and citrate coated CeO2NPs of formula (I) were dispersed into this solution at a final concentration of 2 mg/ml of CeO2 under vigorous stirring. In these conditions, the prepared eye drop formulation was able for pipetting and thus, no errors in the administered dose could be induced by the solution viscosity. - Similar eye drop formulations could also be prepared with hyaluronic acid.
- ARPE19 cells (commercially available) were maintained in Dulbecco's modified Eagle's medium/nutrient mixture F-12 (DMEM/F12), supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin-streptomycin, in a humidified incubator at 37°C and 5%CO2. For all experiments, cells between passages 6 and 12 were used.
- ARPE19 cells (commercially available from ATCC) were seeded in 24-well plates (Sarstedt) at a density of 100.000 cells/ml in complete medium (DMEMF12 + 10% FBS + antibiotic) and incubated for 36h. Cerium oxide nanoparticles of formula (I) were added at final concentrations of cerium oxide of 10 nM, 50 nM, 100 nM and 500 nM (0.0017, 0.0086, 0.0172 and 0.0860 µg/ml) in fresh media and cells were incubated for 24 or 48h more. 100µl of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) were added to each well and cells were incubated 4h. After that, the media was removed and 300µl of DMSO were added to solubilize the formazan crystals. The optical density of each well was measured at 570nm using a microplate spectrophotometer. Data was normalized to untreated cells.
- Intracellular ROS levels were quantified using the H2DCFDA probe. In brief, ARPE19 cells were seeded in 24-well plates at a density of 100.000 cells/ml in complete medium and incubated for 36h. Cerium oxide nanoparticles of formula (I) were added at final concentrations of cerium oxide of 1 nM, 5 nM, 10 nM, 20 nM, 50 nM, 100 nM and 500 nM (from 0.00017 µg/ml to 0.086 µg/ml) in fresh media and incubated for 24h. Cells were washed with PBS 1X , H2DCFDA was added in fresh medium at a final concentration of 10µM and incubated for 30min. Cells were washed again with PBS 1X and exposed to H2O2 (hydrogen peroxide), Antimycin A or tBH (tert-Butyl hydroperoxide) for 1h. Cells were then incubated with lysis buffer for 5min at RT, transferred into a 96-well black plate (VWR) and read immediately in a spectrofluorimeter (Excitation wave length. 485/20; Emission wavelength 528/20). ROS levels were expressed as ratio of mean intensity of sample/mean intensity of control cells.
- Male 8-weeks old C57BL/6N mice purchased at Charles River (France) were used in CeO2NPs of formula (I) biodistribution experiments. Mice were maintained at CELLEX facilities under standard cyclic light conditions (12h light/12h darkness), free access to filtered water and ad libitum food. All experiments were performed according to the Association for Research in Vision and Ophthalmology statement for the use of animals in vision and ophthalmic research and approved by the Vall d'Hebron Research Institute Ethical Committee for Animal Research (VHIR-CEEA) and local governmental authorities.
- For intravitreal administration, mice were anesthetized with inhaled 2% isofluorane (Aerrane®, Baxter laboratories) in an induction chamber and their pupils were dilated with one drop of Tropicamide (Alcon Laboratories). Each animal was afterwards placed on a heating pad with an anaesthetic mask. Under a surgical microscope, a 36-gauge bevelled needle (Hamilton) was inserted in the sclera at approximately 1mm from the superior limbus and 1µl of the correspondent solution (2 mg/ml) was administered (2 µg CeO2 total). The eye fundus was visualized right after in a Micron III (Phoenix Research Lab) platform to corroborate the correct injection.
- For the topical administration, mice were slightly anesthetized with inhaled 2% isofluorane to guarantee a correct absorption and 5µl (10 µg CeO2 total) of the correspondent treatment (eye drop formulation of CeO2NPs of formula (I) giving 2 mg/ml of cerium oxide in the formulation) where placed on the cornea surface of each eye with a micropipette. Mice received the same treatment in both eyes to avoid cross-contamination.
- Mice were euthanized with inhaled CO2 at designated time points post injection. Eyes were enucleated and fixed in 4% PFA (paraformaldehyde - dissolved in 1X PBS) for 30min before dissection under a stereomicroscope. Different ocular parts including anterior pole (cornea and iris), lens, retina, posterior pole (retinal pigment epithelium, choroid and sclera) and optic nerve were dissected and stored at -80°C until digestion. The brain and liver of each animal were also removed, immediately dry frozen and stored at 80°C. Organs were digested in concentrated HNO3 in a 1900 W microwave digestion oven (Milestone, ETHOS EASY). The resultant digestions were diluted with
HNO3 1% (v/v) before being injected in the ICP-MS instrument (Agilent, 7500ce). - At the designated time points post-injection, mice were anesthetized with 1ml ketamine/0.3ml xylazine and transcardially perfused with 4%PFA. Eyes were enucleated and fixed with 4% PFA for 4h at RT and embedded in paraffin blocks. Eye sections of 3µm were cut in a microtome and stored at 4°C. For histological evaluation, slides were deparaffinised in xylene and rehydrated in ethanol at decreasing concentrations. The sections were fixed in ice-cold methanol/acetic acid solution (95:5 v/v) for 1min. Haematoxylin and eosin staining was carried out with a standard protocol and slides were mounted with DPX mounting medium (VWR) and visualized in the microscope.
- Slides were deparaffinised, rehydrated and fixed as described above. After the fixation, slides were washed three times with PBS 1X and antigen retrieval was performed by immersing them in sodium citrate buffer pH 6 and heating them in a pressure cooker for 4min. Samples were blocked with a solution containing 1% (v/v) BSA, 3% (v/v) NGS and 0.5% (v/v) Tween-20 in PBS for 1h at room temperature. Primary antibodies were incubated overnight at 4°C. The following day, samples were washed with PBS and secondary antibodies were incubated 1h at room temperature in darkness. Samples were mounted with Fluoroshield with DAPI and visualized in the confocal microscope (FluoView ASW1.4; Olympus). Primary antibodies used were rabbit anti-GFAP (ab7260, Abcam) and mouse anti-8-OHdG (ab62623, Abcam). Secondary antibodies were Alexa Fluor anti-rabbit 488 (A11008, Thermo) and Alexa Fluor anti-mouse (A11004, Thermo). For the TUNEL staining, slides were deparaffinised as explained above and stained with the TUNEL kit, following manufacturer's instructions (Click-It Plus TUNEL Assay, Invitrogen, Thermo).
- ARPE-19 cells were seeded in a 12-well plate at a density of 100.000cells/ml. After 36h, cerium oxide nanoparticles were added at final concentrations of 50 and 500nM in fresh media and cells were incubated overnight. Cells were exposed to tBH for 4h to induce changes in gene expression. Then, they were washed with PBS 1X and Tri Reagent (Sigma) was added into each well before scrapping the cells. RNA was extracted using manufacturer's protocol. In brief, one microgram of RNA, pre-treated with DNase I (Life Technologies, Thermo), was used to synthetize first strand cDNA using the High-Capacity Reverse Transcription kit (Applied Biosystems, Thermo) with oligo(dT) Primers (Thermo). Quantitative real-time PCR was performed with LightCycler 480 SYBR Green I Master (Roche). Genes analysed were SOD2 and Nrf2. Gene expression was normalized to GAPDH. Animals were euthanized by CO2 inhalation and eyes were immediately enucleated. Eyes were dissected under a stereomicroscope and neural retina, EPR, choroid and sclera were frozen in liquid nitrogen. RNA from the homogenized tissue was extracted using the Tri Reagent standard protocol. Synthesis of cDNA and qPCR were performed as explained above. Genes analysed were GFAP, SOD2 and Nrf2.Gene expression was normalized to B2M.
- Murine eyes of C57BL/6N were immediately enucleated and kept in ice-cold medium before dissection. After removing the cornea and the lens from the anterior of the eye, the central or peripheral choroid-scleral complex was separated from the retina and cut into approximately ∼2 mmx1 mm pieces (rats) or 1 mm×1 mm (mice). Choroid+sclera (here on referred to as "choroid") fragments were isolated without retinal pigment epithelium (RPE) removal by peeling RPE away with forceps and placed in growth factor-reduced Matrigel™ (BD Biosciences, Cat. 354230) seeded in 24 well plates. 30 µL Matrigel ® was used to coat the bottom of 24 well plates without touching the edge of the well. The thickness of Matrigel ®was approximately 0.4 mm. After seeding the choroid, plates were incubated in a 37°C cell culture incubator without medium for 10 minutes in order for the Matrigel™ to solidify. Then, 500 µL of medium EBM-2/EGM (Lonza) was then added to each well and incubated at 37°C with 5% CO2 for 48 hr before any treatment. Then, cells were treated with different concentrations of CeO2 NP-(C) of formula (I) from 0.05 to 500 µM of cerium oxide for 7 days. Medium was changed every 48 hr. Images were taken using an Olympus microscope. Microvessels length was quantified using ImageJ software.
- The laser-induced choroidal neovascularization (LI-CNV) mouse model has been a crucial mainstay model for neovascular AMD. To develop a mouse model with reproducible LI-CNV features, retinas of mice at post-natal week 6-8 (under sedation), were exposed to an intensity of the 430 nm argon laser (4 spots, 100 ms at 250 mW, 50µm area). Then, one group was treated with CeO2NPs of formula (I)-containing eye drops (5µl/drop at 2 mg/ml of cerium oxide in form of CeO2NPs of formula (I)) and the other group was treated with vehicle, during 7 days. Lesions' progression in the exudative area was monitored using optical coherence tomography, fundus imaging and fluorescence angiography and compared with non-treated group in vivo. Eyes were enucleated and posterior pole isolated in ice-cold PBS. Choroid, sclera and RPE layers were isolated from retinas and an immunostaining was performed in flat mount conformation using Iba-1 (Dako) and Isolectin-B4. Lesions areas were quantified using ImageJ software.
- Ceria-NPs of formula (I) were prepared as indicated above in Materials and Methods. TEM image revealed that Ceria-NPs colloids of 3.0-3.5 nm stable in water at concentrations of 1 mg/ml were yielded.
- After the synthesis and characterization of CeO2NPs-(C) of formula (I), its safety in ARPE19 cells with an MTT assay was evaluated. CeO2NPs-(C) of formula (I) incubated during 24 and 48h did not show a reduction in cell viability, at any of the tested concentrations. To test the ability of CeO2NPs-(C) of formula (I) to scavenge intracellular ROS in ARPE19 cells, cells were pre-treated with the nanoparticles during 24h, removed the supernatant and adding new media, before exposing them to different oxidant agents for 1h. Specifically, H2O2, tBH and Antimycin A (AA) were used to induce an oxidative stress response in ARPE19 cells through different pathways. In all cases, a dose-dependent decrease of the ROS levels in cells treated with CeO2NPs-(C) of formula (I) was observed (data not shown). Optical microscope images of ganglion cell layer (GCL) slides in the case of exposure to tBH showed the same results with a decrease of fluorescent signal (8-OHdG, fluorescence intensity in arbitrary units (a.u.) (
FIG. 3 (A) ), indicating the presence of free radicals and their decrease as the concentration of CeO2NPs-(C) of formula (I) increases. Once the decrease of ROS was observed, the question was if this would modify the expression of oxidative stress-related genes. Thus, the antioxidant capacity of CeO2NPs-(C) of formula (I) in these conditions was also evaluated with quantitative real-time PCR. ARPE19 cells were pre-treated with CeO2NPs-(C) of formula (I) during 24h before inducing oxidative stress with tBH for 4h. While the treatment with CeO2NPs-(C) of formula (I) alone did not produce changes in superoxide dismutase-2 (SOD2) expression, cells treated with CeO2NPs-(C) of formula (I) and with induction of oxidative stress experienced a higher increase of SOD2 expression than cells incubated just with tBH (FIG. 3(B) ). CeO2NPs-(C) of formula (I) treatment also induced the upregulation of expression of transcription factor Nrf2 expression (FIG. 3(C) ). Nrf2 is known as the main antioxidant transcription factor, able to protect cells from oxidative stress by inducing the expression of ROS-neutralizing enzymes (Retinal degenerative diseases, book). - Before exploring beneficial therapeutic effects of CeO2NPs-(C) of formula (I), two question where addressed. Does the CeO2NPs-(C) of formula (I) reach the region of interest after drop casting and does the nanoparticles translocate inside the host. For that, intravitreous vs topical administration were prepared and the Ce contents analysed by Inductively coupled plasma mass spectrometry (ICP-MS) as a function of time and organelle.
- Biodistribution assays after intravitreal injection were done, and cerium was detected in the retina several weeks after. Cerium was also able to reach the retina (and all posterior segment structures) after a topical administration in a mouse model of dry AMD.
- The potential of cerium oxide nanoparticles as a therapy for retina degeneration has been tested in vivo in the tubby and vldlr-/- mice models and in the light-damaged rat model but in all cases, through an intravitreal administration. Given the associated complications this route of administration presents, a topical administration rises as a better option.
- To elucidate whether cerium could reach the retina and posterior pole of the eye after a topical administration, a biodistribution assay was performed in C57BL/6N mice receiving CeO2NPs-(C) of formula (I) at three different cerium oxide concentrations (0.1mM; 1mM and 10mM (0.017 mg/ml, 0.172 mg/mg and 1,72 mg/ml) via intravitreal or topical administration. Mice were euthanized 24h after administration and eyes were enucleated and dissected to quantify the amount of cerium present in the different parts of the eye.
- 56.8% of all cerium administered was detected in the eyes of mice receiving intravitreal administration versus an 8.2% in those receiving cerium topically. With topical administration, cerium was homogenously distributed in the different parts of the eye, detecting a 2.1% in the retina. In mice receiving intravitreal administration, cerium was preferentially retained in the retina (21.6%), although it was present in all the eye components. The anterior pole retained a 14% of all cerium administered in the vitreous cavity. Indeed, the distribution is more homogeneous by eye-drops, avoiding damaging the eye with the puncture. In principle the humorous vitreous is a gel highly hydrophilic with 10 nm porosity and negatively charged. Therefore, highly soluble (light and charged), small size and strictly no aggregation is needed for the topical ophthalmological application of the nanoparticles.
- Next Table 1 shows the results of the distribution assay from a concentration of colloid CeO2NPs-(C) of formula (I) at 10 mM (2 mg/ml of cerium oxide) in the aqueous suspension with citrate:
Table 1: Distribution of CeO2NPs-(C) of formula (I) (percentage %), detected by ICP-MS in different parts of eye 24 h after intravitreal or topical administration. Administration Ant. pole Lens Retina Post. pole Total 24h IV injection (2µg) 14% 9,8% 21,6% 11,4% 56,8% Topical (8,6µg) 1,7% 2,3% 2,1% 2,1% 8,2% - Despite the differences in the total amount of cerium detected with the two routes of administration, the concentration reached in the different parts with topical administration was about half of the reached with intravitreal injection. Data are provided in
FIG. 1 , where cerium concentration (ng/mg tissue), detected by ICP-MS is depicted for the different parts of eye after intravitreal or topical administration. No amounts were detected in liver and brain, and no systemic toxicity was observed for the tested compositions in the two modes of administration. - The concentration of cerium reaching the retina after a topical administration is lower than with an intravitreal injection. Therefore, a topical delivery will need a sustained administration to reach the same concentration of cerium in the retina. CeO2NPs-(C) of formula (I) was daily administered at a concentration of cerium oxide of 10mM for one week. After a week, the cerium concentration in the retina was the same achieved with a single intravitreal injection. These data are depicted in bar diagram of
FIG. 2 . InFIG. 2 cerium concentration (ng/mg tissue), detected by ICP-MS is depicted for the different parts of eye. Left column in each set of bars indicates amount detected 24h after topical administration (8.6 µg). Column in the middle of each set of bars indicates amount detected 7 days (7d) after a daily topical administration (60.6 µg after the 7 days). Right bar of each set of bars indicates amount detected 24 h after intravitreal administration (2 µg). Ant. Pole means anterior pole including cornea and iris. Post. pole means posterior pole or segment of eye including retinal pigment epithelium, sclera and choroid). - Cerium accumulated in all parts of the eye at a higher concentration that with intravitreal injection (where the sample remained at the injection point probably due to the inflammation consequence of the puncture), preferentially in the posterior pole. Overall, the amount of cerium detected after a one-week administration was much lower than all cerium administered (6.48 ±1.5 % of total cerium administered; n=4), indicating a high clearance rate.
- Therefore, it can be concluded that aqueous colloidal suspensions of nanoparticles of formula (I) topically administered on the surface of eye (i.e. cornea, conjunctiva, etc.) could surprisingly reach the different structures of the posterior segment in an effective mode. Repeated administration by this more pleasant route is a good substitutive of the dangerous and distressing intravitreal injection, the later non-applicable in early stages of the diseases or conditions of the posterior segment (e.g. in the dry form of AMD). Advantageously, CeO2NPs-(C) of formula (I) did not accumulate in liver or brain at any toxic concentration.
- The effect of cerium accumulation with histological evaluation was also assessed. Retina architecture and the thickness of the different layers was evaluated. No changes were observed in mice receiving CeO2NPs-(C) of formula (I) compared to those receiving vehicle. The thickness of all layers was also maintained between groups. Assessment of the effect of the treatment with CeO2NPs-(C) of formula (I) in cell death was performed by TUNEL staining. Retina sections were evaluated, observing some positive cells in the outer nuclear layer (ONL) and inner nuclear layer (INL), but with no differences between eyes receiving CeO2NPs-(C) of formula (I) or vehicle (data not shown).
- A wide range of physiological stresses and insults can induce Müller glia to undergo reactive gliosis, contributing to retinal degeneration. In order to evaluate the impact of CeO2NPs-(C) of formula (I) accumulation in the increase of reactive gliosis, GFAP expression was analysed. CeO2NPs administration did not increase GFAP expression in wild type retinas, observed with immunofluorescence analysis. Quantification of its expression with real-time PCR did not show any differences in its expression either (data not shown).
- It is known that inflammation may promote aberrant or insufficient angiogenesis. Inventors performed an assay to determine if CeO2NP treatment could inhibit any aberrant form of angiogenesis likely by decreasing inflammation, while promoting, if any, an adequate angiogenesis.
- The effects of CeO2NPs-(C) of formula (I) to avoid aberrant angiogenesis were examined using mouse choroidal sprouting assay. Choroids treated with increased concentrations of CeO2NPs-(C) of formula (I) showed a reduction in newly formed micro-vessels length compared with choroids treated with VEGF (vascular endothelial growth factor). While VEGF promotes microvasculature to grow, CeO2NPs-(C) of formula (I) inhibited choroid sprouting in a dose-dependent manner and better than the control (-VEGF). Data are depicted in
FIG. 4 , wherein micro-vessel length in micrograms is illustrated for each tested concentration and compound. Olympus microscope pictures allow also visualizing the reduction in aberrant angiogenesis by CeO2NPs-(C) of formula (I). - The in vivo study of the inhibition of aberrant angiogenic activity of CeO2NPs-(C) of formula (I) was performed in the mouse model of choroidal neovascularization induced by laser. Ocular treatment with CeO2NPs-(C) of formula (I) during 7 days allowed observing significantly decreased neovascular lesions' areas produced by the laser as well as the activated microglia recruited by the lesion. Data of lesioned area are depicted in
FIG. 5 . - Inventors also carried out an assay with a synthetic vitreous humour to see the distribution of the nanoparticles of the invention (CeO2NPs-(C)) all along the liquid volume. This distribution was compared with that of another colloidal suspension including state of the art ceria nanoparticles stabilized with TMAOH (CeO2NP-TMAOH). These later were those obtained by basic precipitation of cerium nitrate salt in water, and they were in form of aggregates of nanoparticles from 30 nm to 100 nm (including many aggregates around the 100 nm than lower than this size).
- The synthetic vitreous humour (added in a tube) was not as dense as the vitreous humour of mammals, but it served for the purpose of a first approach to see how different ceria nanoparticle (that of the invention and other with aggregates) diffuse all along the different levels of the said vitreous humour.
- Results can be seen in
FIG. 6 , where the percentage of concentration of CeO2NP distributed along the different levels (upper U, middle M or lower L) of the synthetic vitreous humor are shown in bars. CeO2NP were added at the upper level (as shown in figure). - Both type of nanoparticles was able to diffuse all along the vitreous humour, but this was due to the previously mentioned low density of the liquid. The main result of this assay is that with the nanoparticles of the invention (CeO2NPs-(C) of formula (I)) a more homogeneous distribution was achieved, and in addition a higher percentage of the total nanoparticles get the lower level. These slight differences on the behaviour of the nanoparticles are of high relevance in medical conditions because they are translated into an improvement in therapy. Effectively, the therapeutic effect will not depend on the distribution of the nanoparticles. With a synthetic vitreous humour denser as the tested one, and more like that of the mammals, the differences in the distribution between the nanoparticles of formula (I) and those of the prior art (i.e., CeO2NP-TMAOH) are likely to be increased.
-
- Awwad et al., "Principles of Pharmacology in the Eye", British Journal of Pharmacology-2017, vol no. 174 Issue 23, pp.:4205-4223.
- Urtti A et al., "Challenges and obstacles of ocular pharmacokinetics and drug delivery". Adv. Drug. Deliv. Rev. 2006, vol. 58, pp. 1131-1135.
- Simó et al. on behalf of the European Consortium for Early Treatment of Diabetic Retinopathy (EUROCONDOR). "Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications", Br. J. Ophthalmol. -2012, vol. 96, pp.1285-1290
-
US7347987B2 -
US2011111007 - Maccarone et al., 2019. Ophtalmic Applications of Cerium Oxide Nanoparticles. Nanoceria in ophthalmology.
Claims (15)
- A single-crystal single cerium oxide nanoparticle of formula (I):
NP-(C) (I),
wherein
NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3.0 to 5.0 nm, measured with transmission electron microscopy and X-Ray diffraction, and (C) is a coating of citrate molecules adsorbed on the NP,
for use in the treatment of a disorder or disease of the posterior segment of the eye, wherein the treatment comprises administration of a topical ophthalmic dose of single-crystal single cerium oxide nanoparticles of formula (I). - The single-crystal single cerium oxide nanoparticles of formula (I) for use according to claim 1, wherein the crystal diameter is from 3.0 to 3.5 nm, measured with transmission electron microscopy and X-Ray diffraction.
- An aqueous colloidal suspension comprising single-crystal single cerium oxide nanoparticles of formula (I) as defined in any of claims 1-2, and a pharmaceutically acceptable citrate salt, for use in the treatment of a disorder or disease of the posterior segment of the eye, wherein the treatment comprises administration of a topical ophthalmic dose of aqueous colloidal suspension.
- The aqueous colloidal suspension for use according to claim 3, wherein the pharmaceutically acceptable citrate salt is selected from an alkaline and alkaline-earth metal salt.
- The aqueous colloidal suspension for use according to claim 4, wherein the pharmaceutically acceptable citrate salt is sodium citrate.
- The aqueous colloidal suspension for use according to any of claims 3-5, wherein the topical ophthalmic dose is from 1 micrograms of cerium oxide/day to 250 micrograms of cerium oxide/day per eye.
- The aqueous colloidal suspension for use according to any of claims 3-6, which is an eye drop colloidal suspension.
- The single-crystal single cerium oxide nanoparticle of formula (I), or an aqueous colloidal suspension comprising said nanoparticle, for use according to any of claims 1-7, wherein the condition or disease of the posterior segment of the eye is selected from the group consisting of retinal and/or choroid pathologies, vitreous humour pathologies, posterior sclera pathology, intraocular tumors, optic nerve pathologies, and combinations thereof.
- The single-crystal single cerium oxide nanoparticle of formula (I), or an aqueous colloidal suspension comprising said nanoparticle, for use according to any of claims 1-8, wherein the disease of the posterior segment of the eye is a retinal pathology and/or choroid pathology selected from a retinal vasculopathy, a maculopathy, an hereditary eye fundus dystrophy, an idiopathic chorioretinopathy, a central serous retinopathy, generalized choroidal dystrophy, and combinations thereof.
- The single-crystal single cerium oxide nanoparticle of formula (I), or an aqueous colloidal suspension comprising said nanoparticle, for use according to claim 9, wherein the retinal vasculopathy is selected from diabetic retinopathy, diabetic papillopathy, non-diabetic retinopathy, ocular ischemic syndrome, hypertensive retinopathy, thalassemia retinopathy, Coats' syndrome, Eales' syndrome, radiation retinopathy, solar retinopathy, purtscher retinopathy, polypoidal choroidal vasculopathy (PCV), retinal macroaneurysm, retinal microaneurysm, leukemic retinopathy, retinal ischemia, chronic retina disorders, and combinations thereof.
- The single-crystal single cerium oxide nanoparticle of formula (I), or an aqueous colloidal suspension comprising said nanoparticle, for use according to claim 9, wherein the maculopathy is selected from aged-related macular degeneration (AMD), hemorrhagic AMD, retinal angiomatous proliferation, polipoidal choroidal vasculopathy, malattia leventinese, full thickness macular hole, macular epiretinal membrane, macular telangiectasias, cellophane maculopathy or macular pucker, myopia maculopathy, exudative maculopathy after venous thrombosis of the retina, acute macular neuroretinopathy, macular cystoids, macular edema, retinal angioid streaks, choroidal folds, hypotony maculopathy and combinations thereof; and wherein the hereditary eye fundus distrophy is selected from the group consisting of retinitis pigmentosa; atypical retinitis pigmentosa including but not limited to Usher's syndrome, retinitis punctata albicans, Leber's congenital amaurosis, dystrophy of the cones, rod dystrophy, Bietti crystalline corneoretinal dystrophy, juvenile macular dystrophy, all types of macular dystrophy, Stargardt's disease or Fundus flavimaculatus, Usher's Syndrome and combinatios thereof.
- The single-crystal single cerium oxide nanoparticle of formula (I), or an aqueous colloidal suspension comprising said nanoparticle, for use according to any of claims 1-8, wherein the disease of the posterior eye segment is a vitreous humour pathology selected from the group consisting of sub-macular and vitreous haemorrhages, asteroid hyalosis, vitreous detachment, eye floaters or myodesopsia, hereditary vitreoretinopathies, Stickler's syndrome or Wagner's Syndrome, and combinations thereof.
- The single-crystal single cerium oxide nanoparticle of formula (I), or an aqueous colloidal suspension comprising said nanoparticle, for use according to any of claims 1-8, wherein the disease of the posterior segment of the eye is an optic nerve pathology selected from the group consisting of optic atrophy, optic neuritis, neuroretinitis, ischemic neuropathy, hereditary optic neuropathy, toxic amblyopia or nutritional optic neuropathy, ocular hypertension, primary glaucoma , secondary glaucoma, iridocorneal endothelial syndrome associated to glaucoma, head drusen or optic disc drusen, papilledema and combinations thereof.
- A pharmaceutical or veterinary composition comprising:(a) single-crystal single cerium oxide nanoparticles of formula (I):
NP-(C) (I),
wherein
NP is a single-crystal single cerium oxide nanoparticle with a crystal diameter from 3 to 5 nm, measured with transmission electron microscopy and X-Ray diffraction, and (C) is a coating of citrate molecules adsorbed on the NP; and(b) a pharmaceutically or veterinary acceptable citrate salt, together with pharmaceutically or veterinary acceptable excipients and/or carriers. - The pharmaceutical or veterinary composition according to claim 14, which is a topical eye aqueous colloidal suspension.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21382320.6A EP4074319A1 (en) | 2021-04-15 | 2021-04-15 | Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye |
CN202280038522.3A CN117425480A (en) | 2021-04-15 | 2022-04-13 | Topical ophthalmic compositions with cerium oxide nanoparticles for the treatment of posterior segment diseases |
PCT/EP2022/059891 WO2022219050A1 (en) | 2021-04-15 | 2022-04-13 | Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye |
EP22722530.7A EP4322968A1 (en) | 2021-04-15 | 2022-04-13 | Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye |
AU2022258754A AU2022258754A1 (en) | 2021-04-15 | 2022-04-13 | Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye |
IL307730A IL307730A (en) | 2021-04-15 | 2022-04-13 | Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye |
CA3215535A CA3215535A1 (en) | 2021-04-15 | 2022-04-13 | Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21382320.6A EP4074319A1 (en) | 2021-04-15 | 2021-04-15 | Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4074319A1 true EP4074319A1 (en) | 2022-10-19 |
Family
ID=75562694
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21382320.6A Withdrawn EP4074319A1 (en) | 2021-04-15 | 2021-04-15 | Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye |
EP22722530.7A Pending EP4322968A1 (en) | 2021-04-15 | 2022-04-13 | Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22722530.7A Pending EP4322968A1 (en) | 2021-04-15 | 2022-04-13 | Ophthalmic topical composition with ceria nanoparticles for treating diseases of posterior segment of the eye |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP4074319A1 (en) |
CN (1) | CN117425480A (en) |
AU (1) | AU2022258754A1 (en) |
CA (1) | CA3215535A1 (en) |
IL (1) | IL307730A (en) |
WO (1) | WO2022219050A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7347987B2 (en) | 2005-04-29 | 2008-03-25 | University Of Central Florida Research Foundation, Inc. | Inhibition of reactive oxygen species and protection of mammalian cells |
WO2008064357A2 (en) * | 2006-11-22 | 2008-05-29 | University Of Florida Research Foundation, Inc. | Nanoparticles for protection of cells from oxidative stress |
US20100221344A1 (en) * | 2006-04-27 | 2010-09-02 | Sudipta Seal | Functionalized Nanoceria Composition For Ophthalmic Treatment |
US20110111007A1 (en) | 2005-04-29 | 2011-05-12 | Mcginnis James F | Inhibition of retinal cell degeneration or neovascularization by cerium oxide nanoparticles |
WO2017174437A1 (en) * | 2016-04-05 | 2017-10-12 | Hospital Clínic De Barcelona | Ceria nanoparticles for use in the treatment of hepatocellular carcinoma |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018064357A1 (en) | 2016-09-28 | 2018-04-05 | Witricity Corporation | Mitigating false detection of foreign objects in wireless power systems |
-
2021
- 2021-04-15 EP EP21382320.6A patent/EP4074319A1/en not_active Withdrawn
-
2022
- 2022-04-13 WO PCT/EP2022/059891 patent/WO2022219050A1/en active Application Filing
- 2022-04-13 EP EP22722530.7A patent/EP4322968A1/en active Pending
- 2022-04-13 IL IL307730A patent/IL307730A/en unknown
- 2022-04-13 CA CA3215535A patent/CA3215535A1/en active Pending
- 2022-04-13 AU AU2022258754A patent/AU2022258754A1/en active Pending
- 2022-04-13 CN CN202280038522.3A patent/CN117425480A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7347987B2 (en) | 2005-04-29 | 2008-03-25 | University Of Central Florida Research Foundation, Inc. | Inhibition of reactive oxygen species and protection of mammalian cells |
US20110111007A1 (en) | 2005-04-29 | 2011-05-12 | Mcginnis James F | Inhibition of retinal cell degeneration or neovascularization by cerium oxide nanoparticles |
US20100221344A1 (en) * | 2006-04-27 | 2010-09-02 | Sudipta Seal | Functionalized Nanoceria Composition For Ophthalmic Treatment |
WO2008064357A2 (en) * | 2006-11-22 | 2008-05-29 | University Of Florida Research Foundation, Inc. | Nanoparticles for protection of cells from oxidative stress |
WO2017174437A1 (en) * | 2016-04-05 | 2017-10-12 | Hospital Clínic De Barcelona | Ceria nanoparticles for use in the treatment of hepatocellular carcinoma |
Non-Patent Citations (8)
Title |
---|
"European pharmacopoeia", article "Viscosity" |
AWWAD ET AL.: "Principles of Pharmacology in the Eye", BRITISH JOURNAL OF PHARMACOLOGY, vol. 174, no. 23, 2017, pages 4205 - 4223 |
BADIA ANNA ET AL: "Firsts steps in the development of a topical CeO2NPs treatment to fight dry AMD progression using the DKOrd8 mouse model", MEETING INFO: 2018 ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, ARVO 2018, 29 April 2018 (2018-04-29), XP055838006, Retrieved from the Internet <URL:https://iovs.arvojournals.org/article.aspx?articleid=2688980> [retrieved on 20210906] * |
HANCOCK MATTHEW L ET AL: "The characterization of purified citrate-coated cerium oxide nanoparticles prepared via hydrothermal synthesis", APPLIED SURFACE SCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 535, 28 August 2020 (2020-08-28), pages 147681, XP086309227, ISSN: 0169-4332, [retrieved on 20200828], DOI: 10.1016/J.APSUSC.2020.147681 * |
MACCARONE ET AL.: "Ophtalmic Applications of Cerium Oxide Nanoparticles", NANOCERIA IN OPHTHALMOLOGY, 2019 |
SIMO ET AL.: "Br. J. Ophthalmol.", vol. 96, 2012, EUROPEAN CONSORTIUM FOR EARLY TREATMENT OF DIABETIC RETINOPATHY, article "Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications", pages: 1285 - 1290 |
TISI ANNAMARIA ET AL: "Nanoceria Particles Are an Eligible Candidate to Prevent Age-Related Macular Degeneration by Inhibiting Retinal Pigment Epithelium Cell Death and Autophagy Alterations", CELLS, vol. 9, no. 7, 4 July 2020 (2020-07-04), pages 1617, XP055837989, DOI: 10.3390/cells9071617 * |
URTTI A ET AL.: "Challenges and obstacles of ocular pharmacokinetics and drug delivery", ADV. DRUG. DELIV. REV., vol. 58, 2006, pages 1131 - 1135, XP024892105, DOI: 10.1016/j.addr.2006.07.027 |
Also Published As
Publication number | Publication date |
---|---|
CN117425480A (en) | 2024-01-19 |
WO2022219050A1 (en) | 2022-10-20 |
AU2022258754A1 (en) | 2023-11-02 |
IL307730A (en) | 2023-12-01 |
CA3215535A1 (en) | 2022-10-20 |
EP4322968A1 (en) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yadav et al. | Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD) | |
Tahara et al. | Feasibility of drug delivery to the eye's posterior segment by topical instillation of PLGA nanoparticles | |
Shokry et al. | Exploring gelatin nanoparticles as novel nanocarriers for Timolol Maleate: augmented in-vivo efficacy and safe histological profile | |
Ahmed et al. | Ocular drug delivery: a comprehensive review | |
Srinivasarao et al. | Fundamentals, challenges, and nanomedicine‐based solutions for ocular diseases | |
Cholkar et al. | Novel strategies for anterior segment ocular drug delivery | |
US9878000B2 (en) | Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof | |
Mehra et al. | Safety and toxicity of nanomaterials for ocular drug delivery applications | |
Zhang et al. | Ten years of knowledge of nano-carrier based drug delivery systems in ophthalmology: current evidence, challenges, and future prospective | |
Nagai et al. | A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure | |
Reimondez-Troitiño et al. | Polymeric nanocapsules: a potential new therapy for corneal wound healing | |
Chen et al. | Tacrolimus loaded cationic liposomes for dry eye treatment | |
Aboali et al. | Curcumin-loaded proniosomal gel as a biofreindly alternative for treatment of ocular inflammation: In-vitro and in-vivo assessment | |
Formica et al. | Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications | |
Naguib et al. | 3D printed ocusert laden with ultra-fluidic glycerosomes of ganciclovir for the management of ocular cytomegalovirus retinitis | |
Wei et al. | Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy | |
Zhang et al. | A novel eyes topical drug delivery system: CsA-LNC for the treatment of DED | |
Xu et al. | Deliver protein across bio-barriers via hexa-histidine metal assemblies for therapy: a case in corneal neovascularization model | |
Yang et al. | Highly effective corneal permeability of reactive oxygen species-responsive nano-formulation encapsulated cyclosporine a for dry eye management | |
Li et al. | Optimization and characterization of low-molecular-weight chitosan-coated baicalin mPEG-PLGA nanoparticles for the treatment of cataract | |
Qi et al. | Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery | |
Sanap et al. | Ophthalmic nano-bioconjugates: critical challenges and technological advances | |
Yordanova Andonova | A new direction in ophthalmic development: Nanoparticle drug delivery systems | |
Wang et al. | Evaluation of His6-Metal Assemblies as a Drug Delivery Vehicle in the Treatment of Anterior Segment Disease Using a Corneal Inflammation Model | |
Su et al. | Depot unilamellar liposomes to sustain transscleral drug Co-delivery for ophthalmic infection therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230420 |